lansoprazole has been researched along with Esophageal Reflux in 308 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| " lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis." | 10.20 | Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003) |
| "Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double-blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days." | 9.30 | Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. ( Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J, 2019) |
| "To compare the clinical efficacy of the second-generation H2RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease (GERD)." | 9.22 | Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 9.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
| "GERD patients with dyspepsia were enrolled and treated with lansoprazole 15 or 30 mg once daily for 4 weeks." | 9.19 | Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. ( Haruma, K; Kinoshita, Y; Miwa, H; Miyata, K; Sanada, K, 2014) |
| "Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment." | 9.17 | Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "After step-down to once-daily dexlansoprazole MR 30 mg, heartburn remained well controlled in 88% of patients (125 of 142)." | 9.16 | Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. ( Fass, R; Han, C; Inadomi, J; Mody, R; O'Neil, J; Perez, MC, 2012) |
| "To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 9.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
| "To assess the 12-month safety of dexlansoprazole MR in patients with symptomatic gastro-oesophageal reflux disease (GERD)." | 9.15 | The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. ( Atkinson, SN; Dabholkar, AH; Han, C; Paris, MM; Perez, MC; Peura, DA, 2011) |
| "Patients (N=305) with frequent, moderate-to-very severe nocturnal heartburn and associated sleep disturbances were randomized 1:1 in a double-blind fashion to receive dexlansoprazole MR or placebo once daily for 4 weeks." | 9.15 | The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. ( Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN, 2011) |
| "To assess the efficacy and safety of lansoprazole in treating infants with symptoms attributed to gastroesophageal reflux disease (GERD) that have persisted despite a >or= 1-week course of nonpharmacologic management." | 9.14 | Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. ( Atkinson, S; Furmaga-Jablonska, W; Hassall, E; Orenstein, SR; Raanan, M, 2009) |
| "The acceptability of pharmaceutical formulations of lansoprazole in capsules and orally disintegrating tables is similar among patients with gastroesophageal reflux disease and associated dysphagia." | 9.14 | [Evaluation of preferences in patients with gastroesophageal reflux disease and dysphagia concerning treatment with lansoprazole orally disintegrating tablets]. ( Armengol, S; Blanco, MA; Heras, J; Mas, M; Mearin, F; Piqué, JM; Plazas, MJ; Prieto, M, 2009) |
| "Double-blind placebo-controlled crossover study investigating effect of lansoprazole on chest pain; 125 patients with angiographically proven coronary artery disease enrolled with at least one weekly episode of nocturnal/rest pain, randomized to lansoprazole 30 mg daily or placebo with crossover after 4 weeks." | 9.14 | Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo. ( Bankart, MJ; de Caestecker, JS; Gershlick, AH; Talwar, V; Wurm, P, 2010) |
| "Proton pump inhibitors such as lansoprazole are used in the treatment of gastroesophageal reflux disease (GERD), but dosing guidelines for infants have not been determined." | 9.13 | Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux. ( Dhume, P; Khoshoo, V, 2008) |
| "To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease." | 9.12 | Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. ( De Micheli, E; Frazzoni, M; Manno, M; Savarino, V, 2006) |
| "Out of 45 patients referred for unexplained chronic persistent cough, 36 had at least one of the GI investigations (endoscopy, 24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI) therapy) positive and were randomly assigned to receive either 30 mg lansoprazole o." | 9.12 | Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. ( Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F, 2006) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 13 and 24 months of age with gastroesophageal reflux disease (GERD)." | 9.12 | Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ( Amer, F; Chiu, YL; Heyman, MB; Huang, B; Winter, HS; Zhang, W, 2007) |
| "To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease." | 9.11 | Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. ( Chan, AO; Hu, WH; Huang, JQ; Hui, WM; Lai, KC; Lam, CL; Lam, KF; Lam, SK; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2004) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 9.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 9.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| " continuous treatment with lansoprazole 15 mg daily in patients with endoscopy-negative gastro-oesophageal reflux disease." | 9.11 | Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. ( Anderson, M; Chapman, R; Duggan, S; McKeith, D; Rosen, JP; Shepherd, A; Tsai, HH; Vearer, D, 2004) |
| "To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis." | 9.11 | Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005) |
| "In an open-label, two-way crossover study, 45 Helicobacter pylori-negative patients with gastro-oesophageal reflux disease were randomized to receive one of two regimens: 30 mg lansoprazole or esomeprazole 40 mg once daily." | 9.11 | A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. ( Brooks, W; Doviak, M; Hornbuckle, K; Johnson, DA; Ryan, M; Stacy, T; Willis, J; Wootton, T, 2005) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 9.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 9.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
| ": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily." | 9.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain." | 9.10 | Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. ( Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2003) |
| "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age." | 9.10 | Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002) |
| "To evaluate the pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability of lansoprazole in adolescents between 12 and 17 years of age with gastroesophageal reflux disease (GERD)." | 9.10 | Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ( Chiu, YL; Fitzgerald, J; Gremse, D; Gunasekaran, T; Gupta, S; Karol, M; Keith, R; Pan, WJ, 2002) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD)." | 9.10 | Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ( Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H, 2002) |
| "Lansoprazole and omeprazole are widely used proton pump inhibitors for the management of gastro-oesophageal reflux." | 9.10 | Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "The aim of the present study was to investigate whether not only omeprazole but also lansoprazole leads to hypertrophy of the parietal cells of the gastric mucosa." | 9.09 | Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. ( Alexandridis, T; Meining, A; Seifert, E; Stolte, M, 2000) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 9.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists." | 9.09 | Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000) |
| "Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg p." | 9.09 | Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. ( Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM, 2001) |
| "Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks." | 9.08 | Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 9.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 9.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| "Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux." | 9.08 | Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998) |
| "Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease." | 8.87 | Dexlansoprazole MR for the management of gastroesophageal reflux disease. ( Behm, BW; Peura, DA, 2011) |
| "To describe the pharmacology, pharmacokinetics, and efficacy of dexlansoprazole in the treatment of heartburn associated with nonerosive gastroesophageal reflux disease (GERD) and healing and maintenance of healing of all grades of erosive esophagitis (EE)." | 8.86 | Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. ( Abel, C; Desilets, AR; Willett, K, 2010) |
| "Dexlansoprazole modified release (dexlansoprazole MR) is an orally administered delayed-release formulation of the R-enantiomer of the proton pump inhibitor lansoprazole that is effective in improving the healing of all grades of erosive oesophagitis, maintaining the healing of erosive oesophagitis and in the treatment of symptomatic non-erosive reflux disease (NERD)." | 8.86 | Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. ( Croxtall, JD; Scott, LJ, 2010) |
| "The older proton pump inhibitor (PPI) omeprazole and the newer PPIs lansoprazole, rabeprazole, and pantoprazole are approved for the acute and maintenance treatment of gastroesophageal reflux disease (GERD)." | 8.81 | Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. ( Caro, JJ; Salas, M; Ward, A, 2001) |
| " In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment." | 7.79 | The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "The objective of this study was to formulate and evaluate the lansoprazole (LPZ)-loaded microparticles to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease (GERD)." | 7.79 | A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. ( Alai, M; Lin, WJ, 2013) |
| "Although some cases of collagenous colitis have been induced by lansoprazole (LPZ), the clinicopathologic features of LPZ-associated collagenous colitis have not been elucidated." | 7.74 | Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis. ( Gushima, M; Hirakawa, K; Hirano, A; Iida, M; Jo, Y; Kudo, T; Matsumoto, T; Nakamura, S; Nakashima, Y; Umeno, J; Yada, S; Yamagata, H; Yao, T; Yoshimura, R, 2008) |
| "To assess the acceptability of lansoprazole orally disintegrating tablets (LODT) in patients with gastro-oesophageal reflux disease (GORD)." | 7.74 | Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study. ( de Argila, CM; Galván, J; Heras, J; Márquez, E; Plazas, MJ; Ponce, J; Porcel, J, 2007) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 7.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 7.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| "To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease." | 7.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
| "To determine if patients perceived a difference in the efficacy, side effects, and value of omeprazole versus lansoprazole for gastroesophageal reflux disease (GERD) maintenance therapy after a formulary conversion, and to evaluate the costs of the conversion." | 7.70 | Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy. ( Condra, LJ; Marcus, D; Morreale, AP; Stolley, SN, 1999) |
| "Lansoprazole intolerance requiring omeprazole conversion occurred in 5% of veterans on proton pump inhibitor therapy for chronic gastro-oesophageal reflux disease (GERD) symptoms and in 10% of patients with prior omeprazole success." | 7.70 | Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. ( Fass, R; Gerson, LB; Hatton, BN; Jones, W; Pulliam, G; Ryono, R; Sampliner, RE; Triadafilopoulos, G, 2000) |
| "Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment." | 6.82 | Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. ( Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016) |
| "In this open-label, 3-way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5-7-day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10-17-day washout periods." | 6.75 | Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. ( Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J, 2010) |
| "Only patients with GERD had significantly (P = 0." | 6.75 | Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. ( Garrett, CG; Goutte, M; Hagaman, D; Jerome, WG; Slaughter, JC; Smith, BS; Vaezi, MF; Washington, MK, 2010) |
| " Both studies involved either a 7- or 14-day pre-treatment period, with a dose administration period of 5 days, and a follow-up period of 30 days for adverse events collection." | 6.73 | Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year. ( Atkinson, S; North, J; Raanan, M; Springer, M, 2008) |
| "The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 6.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
| " Safety for all study participants was monitored by adverse event reports and laboratory evaluations." | 6.70 | Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 6.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| "Lansoprazole is a proton pump inhibitor that inactivates the H(+)/K(+)-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH." | 6.43 | Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. ( Croom, KF; Scott, LJ, 2005) |
| " lansoprazole, 15 mg once daily, for the maintenance treatment of patients with healed reflux oesophagitis." | 6.20 | Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. ( Bayerdörffer, E; Bigard, MA; De Freitas, D; Devière, J; Eklund, S; Fried, M; Kristjánsdóttir, S; Larkö, A; Lauritsen, K; Morris, J; Mózsik, G; Murray, F; Orive, V; Rodrigo, L; Savarino, V; Schneider, H; Vetvik, K, 2003) |
| "The prospective, open-label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD)." | 5.34 | Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. ( Chang, TE; Hou, MC; Huang, YH; Lee, FY; Lin, XH; Luo, JC; Ting, PH, 2020) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 5.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 5.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "Both PPIs are approved for the treatment of gastroesophageal reflux disease (GERD) and are commonly converted in therapeutic interchange programs." | 5.31 | Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole. ( Ehlert, DA; Geurkink, EA; Nelson, WW; Reichelderfer, M; Vermeulen, LC, 2000) |
| "Patients (n = 32) with endoscopically confirmed erosive oesophagitis who experienced heartburn at least once a week were randomised in a double-blind manner to receive either daily vonoprazan (20 mg) or lansoprazole (30 mg) before breakfast for 14 days." | 5.30 | Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis. ( Arai, E; Fukui, H; Kondo, T; Miwa, H; Oshima, T; Taki, M; Tomita, T; Watari, J, 2019) |
| "To compare the clinical efficacy of the second-generation H2RA lafutidine with that of lansoprazole in Japanese patients with mild gastroesophageal reflux disease (GERD)." | 5.22 | Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease. ( Haruma, K; Inoue, M; Kawano, S; Kinoshita, Y; Komatsu, H; Komazawa, Y; Kushiyama, Y; Manabe, N; Mukai, S; Nagata, S; Okada, H; Okanobu, H; Onogawa, S; Takenaka, R; Tanaka, S; Todo, H; Yoshinaga, F, 2016) |
| "Asthma control as measured by the Asthma Control Questionnaire (ACQ) and other questionnaires from a 6-month clinical trial of lansoprazole in children with asthma was analyzed for associations with surrogates of lansoprazole exposure (based on treatment assignment and metabolizer phenotype)." | 5.20 | Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype. ( Holbrook, JT; Lang, JE; Lima, JJ; Mougey, EB; Teague, WG; Wei, CY; Wise, RA, 2015) |
| "GERD patients with dyspepsia were enrolled and treated with lansoprazole 15 or 30 mg once daily for 4 weeks." | 5.19 | Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia. ( Haruma, K; Kinoshita, Y; Miwa, H; Miyata, K; Sanada, K, 2014) |
| "Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment." | 5.17 | Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "Dexlansoprazole MR 30 mg once daily (QD) is approved in adults for the treatment of symptomatic nonerosive gastroesophageal reflux disease (GERD) and maintenance of healed erosive esophagitis (EE); 60 mg is approved for healing EE." | 5.16 | Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD. ( Kukulka, M; Perez, MC; Wu, J, 2012) |
| "After step-down to once-daily dexlansoprazole MR 30 mg, heartburn remained well controlled in 88% of patients (125 of 142)." | 5.16 | Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. ( Fass, R; Han, C; Inadomi, J; Mody, R; O'Neil, J; Perez, MC, 2012) |
| "To determine whether lansoprazole is effective in reducing asthma symptoms in children without overt GER." | 5.16 | Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. ( Blake, K; Brown, ED; Castro, M; Dozor, AJ; Gold, BD; Holbrook, JT; Lima, JJ; Mastronarde, JG; Sockrider, MM; Teague, WG; Wise, RA, 2012) |
| "The purpose of this 24-week treatment study was to evaluate the effects of three treatment strategies after 8 weeks of lansoprazole therapy for gastroesophageal reflux disease in children." | 5.15 | The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children. ( Choe, YH; Kim, MJ; Lee, JH; Lee, JS, 2011) |
| "To assess the 12-month safety of dexlansoprazole MR in patients with symptomatic gastro-oesophageal reflux disease (GERD)." | 5.15 | The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. ( Atkinson, SN; Dabholkar, AH; Han, C; Paris, MM; Perez, MC; Peura, DA, 2011) |
| "Patients (N=305) with frequent, moderate-to-very severe nocturnal heartburn and associated sleep disturbances were randomized 1:1 in a double-blind fashion to receive dexlansoprazole MR or placebo once daily for 4 weeks." | 5.15 | The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. ( Fass, R; Han, C; Johnson, DA; Mody, R; Orr, WC; Perez, MC; Pilmer, BL; Stern, KN, 2011) |
| "To compare the effects of immediate-release omeprazole and 2 different delayed-release proton pump inhibitors on 24-hour intragastric acidity in gastroesophageal reflux disease patients." | 5.14 | Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD. ( Bagin, RG; Ballard, ED; Gautille, TC; Howden, CW; Koch, FK, 2009) |
| "To assess the efficacy and safety of lansoprazole in treating infants with symptoms attributed to gastroesophageal reflux disease (GERD) that have persisted despite a >or= 1-week course of nonpharmacologic management." | 5.14 | Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. ( Atkinson, S; Furmaga-Jablonska, W; Hassall, E; Orenstein, SR; Raanan, M, 2009) |
| "Esomeprazole may be more effective than omeprazole, lansoprazole, and pantoprazole for the rapid relief of heartburn symptoms and acid reflux symptoms in patients with reflux esophagitis." | 5.14 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009) |
| "The acceptability of pharmaceutical formulations of lansoprazole in capsules and orally disintegrating tables is similar among patients with gastroesophageal reflux disease and associated dysphagia." | 5.14 | [Evaluation of preferences in patients with gastroesophageal reflux disease and dysphagia concerning treatment with lansoprazole orally disintegrating tablets]. ( Armengol, S; Blanco, MA; Heras, J; Mas, M; Mearin, F; Piqué, JM; Plazas, MJ; Prieto, M, 2009) |
| "Double-blind placebo-controlled crossover study investigating effect of lansoprazole on chest pain; 125 patients with angiographically proven coronary artery disease enrolled with at least one weekly episode of nocturnal/rest pain, randomized to lansoprazole 30 mg daily or placebo with crossover after 4 weeks." | 5.14 | Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo. ( Bankart, MJ; de Caestecker, JS; Gershlick, AH; Talwar, V; Wurm, P, 2010) |
| "To determine the pharmacokinetics of lansoprazole in neonates and infants <1 year of age with gastroesophageal reflux disease (GERD)-associated symptoms." | 5.13 | Age-dependent pharmacokinetics of lansoprazole in neonates and infants. ( Atkinson, S; Kukulka, M; North, J; Sutkowski-Markmann, D; Witt, G; Zhang, W, 2008) |
| "To compare the efficacy of esomeprazole and lansoprazole at their standard dosages in suppressing oesophageal acid exposure in complicated gastro-oesophageal reflux disease." | 5.12 | Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole. ( De Micheli, E; Frazzoni, M; Manno, M; Savarino, V, 2006) |
| "Out of 45 patients referred for unexplained chronic persistent cough, 36 had at least one of the GI investigations (endoscopy, 24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI) therapy) positive and were randomly assigned to receive either 30 mg lansoprazole o." | 5.12 | Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole. ( Baldi, F; Cappiello, R; Cavoli, C; Ghersi, S; Roda, E; Torresan, F, 2006) |
| "The aim was to compare esomeprazole with lansoprazole for the maintenance of healed erosive esophagitis and resolution of gastroesophageal reflux disease-related symptoms in a United States population." | 5.12 | Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. ( Devault, KR; Johanson, JF; Johnson, DA; Liu, S; Sostek, MB, 2006) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 13 and 24 months of age with gastroesophageal reflux disease (GERD)." | 5.12 | Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease. ( Amer, F; Chiu, YL; Heyman, MB; Huang, B; Winter, HS; Zhang, W, 2007) |
| "To compare the effect of lansoprazole 30 mg and 15 mg once daily on the 24-h oesophageal and intragastric pH profiles in Chinese patients with gastro-oesophageal reflux disease." | 5.11 | Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease. ( Chan, AO; Hu, WH; Huang, JQ; Hui, WM; Lai, KC; Lam, CL; Lam, KF; Lam, SK; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2004) |
| "To determine the clinical value of an empirical trial of high-dose lansoprazole in detecting patients with gastro-oesophageal reflux disease-related non-cardiac chest pain." | 5.11 | The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial. ( Bautista, J; Briseno, M; Cui, H; Fass, R; Fullerton, H, 2004) |
| "To compare the effect of esomeprazole 40 mg with lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg on intragastric pH during single and repeated dosing in four separate studies in patients with symptoms of gastro-oesophageal reflux disorder (GERD)." | 5.11 | Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. ( Lind, T; Röhss, K; Wilder-Smith, C, 2004) |
| " continuous treatment with lansoprazole 15 mg daily in patients with endoscopy-negative gastro-oesophageal reflux disease." | 5.11 | Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. ( Anderson, M; Chapman, R; Duggan, S; McKeith, D; Rosen, JP; Shepherd, A; Tsai, HH; Vearer, D, 2004) |
| "We followed up 295 pregnancies exposed to omeprazole [233 in the first trimester (T1)], 62 to lansoprazole (55 in T1) and 53 to pantoprazole (47 in T1), and compared pregnancy outcome to that of 868 European Network of Teratology Information Services controls." | 5.11 | The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. ( Arnon, J; Clementi, M; De Santis, M; Diav-Citrin, O; Malm, H; Ornoy, A; Robert-Gnansia, E; Schaefer, C; Shechtman, S; Valti, E; van Tonningen, MR, 2005) |
| "To assess the efficacy and safety of lansoprazole in the treatment of adolescents with symptomatic, endoscopically proven, non-erosive gastroesophageal reflux disease and erosive esophagitis." | 5.11 | Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. ( Fiedorek, S; Gold, BD; Gremse, D; Huang, B; Lee, C; Stolle, J; Tolia, V, 2005) |
| " We investigated the heartburn symptoms of patients with gastro-oesophageal reflux disease during sequential treatment with 40 mg of famotidine or 15 mg of lansoprazole to clarify whether H." | 5.11 | Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole. ( Adachi, K; Amano, Y; Fujishiro, H; Furuta, K; Hashimoto, T; Hattori, S; Ishihara, S; Kinoshita, Y; Komazawa, Y; Mihara, T, 2005) |
| "In an open-label, two-way crossover study, 45 Helicobacter pylori-negative patients with gastro-oesophageal reflux disease were randomized to receive one of two regimens: 30 mg lansoprazole or esomeprazole 40 mg once daily." | 5.11 | A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease. ( Brooks, W; Doviak, M; Hornbuckle, K; Johnson, DA; Ryan, M; Stacy, T; Willis, J; Wootton, T, 2005) |
| "Heartburn, regurgitation and dysphagia were hardly found in any group at 8 weeks after 15 mg or 30 mg lansoprazole treatment." | 5.11 | Management of symptoms in step-down therapy of gastroesophageal reflux disease. ( Iida, T; Kishikawa, H; Mine, S; Tabata, T; Tanaka, Y, 2005) |
| "Daily asthma symptoms, albuterol use, peak expiratory flow, FEV1, FVC, and investigator-assessed asthma symptoms at 24 weeks did not improve significantly with lansoprazole treatment compared to placebo." | 5.11 | Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. ( Ballard, ED; Huang, B; Leung, FW; Littner, MR; Samra, NK, 2005) |
| "To compare the efficacy and safety of on-demand lansoprazole 15 mg and placebo treatment in patients with gastro-oesophageal reflux." | 5.11 | Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. ( Bigard, MA; Genestin, E, 2005) |
| ": Fifty patients with complicated or atypical gastro-oesophageal reflux disease were randomly assigned to receive 30 mg lansoprazole (n = 26) or 40 mg pantoprazole (n = 24) once daily." | 5.10 | Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2003) |
| "Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain." | 5.10 | Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. ( Chan, CK; Chen, WH; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Lau, CP; Wong, BC; Wong, NY; Wong, WM; Xia, HH, 2003) |
| "To assess the efficacy of lansoprazole for the relief of symptoms due to gastroesophageal reflux disease (GERD) in children 1 to 11 years of age." | 5.10 | Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Book, L; Ferry, G; Gunasekaran, T; Huang, B; Keith, R; Tolia, V, 2002) |
| "To evaluate the pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability of lansoprazole in adolescents between 12 and 17 years of age with gastroesophageal reflux disease (GERD)." | 5.10 | Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability. ( Chiu, YL; Fitzgerald, J; Gremse, D; Gunasekaran, T; Gupta, S; Karol, M; Keith, R; Pan, WJ, 2002) |
| "To evaluate the pharmacokinetics and pharmacodynamics of lansoprazole in children between 1 and 11 years of age with gastroesophageal reflux disease (GERD)." | 5.10 | Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. ( Book, L; Chiu, YL; Gremse, D; Gunasekaran, T; Karol, M; Pan, WJ; Pilmer, B; Tolia, V; Winter, H, 2002) |
| "This randomized, open-label, comparative five-way crossover study evaluated the 24-h intragastric pH profile of oral esomeprazole 40 mg, lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg, and rabeprazole 20 mg once daily in 34 Helicobacter pylori-negative patients aged 18-60 yr with symptoms of gastroesophageal reflux disease." | 5.10 | Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. ( Chen, Y; Katz, PO; Miner, P; Sostek, M, 2003) |
| "Lansoprazole and omeprazole are widely used proton pump inhibitors for the management of gastro-oesophageal reflux." | 5.10 | Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "Fifty patients with complications or atypical manifestations of gastro-oesophageal reflux disease were given lansoprazole, 30 mg once daily." | 5.10 | Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. ( De Micheli, E; Frazzoni, M; Grisendi, A; Savarino, V, 2002) |
| "The aim of the present study was to investigate whether not only omeprazole but also lansoprazole leads to hypertrophy of the parietal cells of the gastric mucosa." | 5.09 | Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach. ( Alexandridis, T; Meining, A; Seifert, E; Stolte, M, 2000) |
| "05) lower percentages of days and nights with heartburn, less pain severity of both day and night heartburn, fewer days of antacid use, and smaller amounts of antacid use compared with patients who were treated with ranitidine or placebo." | 5.09 | Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. ( Campbell, DR; Fludas, C; Huang, B; Kahrilas, PJ; Richter, JE, 2000) |
| "To determine efficacy of lansoprazole, a relatively new proton pump inhibitor, on symptoms and oesophagitis in a group of children with gastro-oesophageal reflux disease refractory to H2 receptor antagonists." | 5.09 | Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood. ( Cucchiara, S; De Rosa, I; Franco, MT; Iula, VD; Salvia, G; Spadaro, R; Terrin, G, 2000) |
| "Patients diagnosed with idiopathic chronic laryngitis were randomized to receive either lansoprazole 30 mg p." | 5.09 | Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. ( Buchner, A; El-Serag, HB; Gavin, M; Inadomi, JM; Lee, P; McCarthy, DM, 2001) |
| "Our objective was to compare four management strategies for heartburn: therapy with an H2-receptor antagonist (ranitidine), therapy with a proton pump inhibitor (lansoprazole), crossover from ranitidine to lansoprazole ("step-up" therapy), and crossover from lansoprazole to ranitidine ("step-down" therapy)." | 5.09 | Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. ( Freston, JW; Henning, JM; Howden, CW; Huang, B; Lukasik, N, 2001) |
| "Six hundred and four patients with endoscopically proven oesophagitis and a recent history of heartburn were randomly assigned to receive lansoprazole 30 mg or omeprazole 20 mg daily for 4-8 weeks." | 5.08 | Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. ( Mee, AS; Rowley, JL, 1996) |
| " pylori and with gastro-oesophageal reflux disease we investigated the gastritis parameters in antral and corpus mucosa before and after 2, 6 and 12 months of treatment with 15 or 30 mg lansoprazole or 20 mg omeprazole/day." | 5.08 | Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease. ( Alexandridis, T; Meining, A; Schmitz, JM; Seifert, E; Stolte, M, 1998) |
| "After healing and symptom relief had been obtained on open therapy with lansoprazole 30 mg daily, 103 patients with reflux oesophagitis grade 1 or 2 were randomized to maintenance therapy with lansoprazole 15 or 30 mg daily, and time until recurrence of symptoms and/or endoscopic changes was recorded." | 5.08 | Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole. ( Berstad, A; Hatlebakk, JG, 1997) |
| "In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease." | 5.08 | A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998) |
| " However, lansoprazole appears to have a more rapid onset of reduction of acid gastro-oesophageal reflux than omeprazole over a 48 h period." | 5.08 | Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis. ( Burnham, WR; Kamm, MA; Newton, M, 1998) |
| "Lansoprazole (LAN) and omeprazole (OME) heal esophagitis effectively and to similar extents, but LAN has a faster effect on the relief of symptoms of gastroesophageal reflux." | 5.08 | Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease. ( Hammarlund, B; Iwarzon, M; Janczewska, I; Sagar, M; Seensalu, R; Sjöstedt, S, 1998) |
| " After undergoing 1 year of voriconazole therapy for pulmonary aspergillosis, a 44-year-old man began treatment with 30 mg lansoprazole for gastroesophageal reflux symptoms." | 4.93 | Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature. ( Lopez, JL; Tayek, JA, 2016) |
| "Dexlansoprazole modified release (MR; Dexilant™), the R-enantiomer of lansoprazole, was approved in the USA in 2009 for the management of erosive esophagitis and nonerosive reflux disease." | 4.87 | Dexlansoprazole MR for the management of gastroesophageal reflux disease. ( Behm, BW; Peura, DA, 2011) |
| "Dexlansoprazole modified release (dexlansoprazole MR) is an orally administered delayed-release formulation of the R-enantiomer of the proton pump inhibitor lansoprazole that is effective in improving the healing of all grades of erosive oesophagitis, maintaining the healing of erosive oesophagitis and in the treatment of symptomatic non-erosive reflux disease (NERD)." | 4.86 | Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. ( Croxtall, JD; Scott, LJ, 2010) |
| " We report 3 cases of anaphylactic reactions induced by lansoprazole or ranitidine diagnosed in a population of 8304 first-referral patients over a 13-year period." | 4.83 | Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature. ( Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G, 2006) |
| " Although PPIs have been introduced into the therapy of acute peptic ulcer disease at different daily, oral doses of 20 mg (omeprazole and rabeprazole), 30 mg (lansoprazole) and 40 mg (pantoprazole), the data suggest that the optimal dose of lansoprazole, omeprazole and pantoprazole, with respect to the acute treatment of peptic ulcers and moderate to severe gastroesophageal reflux disease (GERD), is about 30-40 mg daily." | 4.80 | Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. ( Horbach, S; Kromer, W; Lühmann, R, 1999) |
| "Aim of this overview was to evaluate the main clinical trials with lansoprazole published from 1997 to 1999 in English-language journals, regarding gastroesophageal reflux disease, peptic ulcer, NSAID-induced ulcer, and ZES." | 4.80 | [Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999]. ( Capurso, L; Dobrilla, G, 2000) |
| " In the treatment of gastric ulcer, analysis of all studies that have compared lansoprazole, a newly developed proton pump inhibitor, and H2-receptor antagonists has shown a statistically significant difference for a higher healing rate with lansoprazole." | 4.78 | Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer. ( Florent, C, 1993) |
| "GERD patients with dyspepsia were treated with lansoprazole 15 mg or 30 mg daily for four weeks." | 3.81 | Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: primary care perspectives from the LEGEND study. ( Haruma, K; Hiroi, S; Kinoshita, Y; Miwa, H; Sakamoto, S; Sanada, K, 2015) |
| " The dose of lansoprazole needed to heal the esophagitis was not significantly associated with the risk for clinical relapse (hazard ratio [HR] 1." | 3.80 | High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents. ( Brito, HS; Kawakami, E; Machado, RS; Ogata, SK; Yamamoto, E, 2014) |
| " In addition, because patients with higher BMI have more severe symptoms at baseline, they may experience greater therapeutic gain with dexlansoprazole (NERD and erosive oesophagitis) and possibly lansoprazole (erosive oesophagitis) treatment." | 3.79 | The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole. ( Hunt, B; Mody, R; Perez, MC; Peura, DA; Pilmer, B, 2013) |
| "The objective of this study was to formulate and evaluate the lansoprazole (LPZ)-loaded microparticles to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease (GERD)." | 3.79 | A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation. ( Alai, M; Lin, WJ, 2013) |
| " 10 infants suspected of having GERD (gastroesophageal reflux) received oral lansoprazole therapy by tube administration." | 3.78 | Does oral lansoprazole really reduce gastric acidity in VLBW premature neonates? ( Ong, KK; Rogers, IM; Samuel, KF; Singh, A; Tham, SY, 2012) |
| "We aimed to investigate effects of the proton pump inhibitors (PPIs) omeprazole, lansoprazole and pantoprazole, which are currently used for the treatment of hyperacidity and gastro-oesophageal reflux, on the reactivity of the isolated rat lower oesophageal sphincter." | 3.77 | Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter. ( Buyukafsar, K; Erenmemisoglu, A; Ozkur, M; Pektas, M; Un, I; Yurtsever, AS, 2011) |
| " pylori-negative subjects with erosive esophagitis (>or= grade 2; n=196), nonerosive reflux disease (n=688), or functional dyspepsia (n=711) who participated in US Takeda-sponsored lansoprazole trials." | 3.76 | Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients. ( Atkinson, S; Haber, MM; Hunt, B; Peura, DA, 2010) |
| "Although some cases of collagenous colitis have been induced by lansoprazole (LPZ), the clinicopathologic features of LPZ-associated collagenous colitis have not been elucidated." | 3.74 | Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis. ( Gushima, M; Hirakawa, K; Hirano, A; Iida, M; Jo, Y; Kudo, T; Matsumoto, T; Nakamura, S; Nakashima, Y; Umeno, J; Yada, S; Yamagata, H; Yao, T; Yoshimura, R, 2008) |
| "To determine if patients with gastro-oesophageal reflux disease (GERD), who were previously managed on lansoprazole 30 mg twice daily, could be maintained on rabeprazole 20 mg once daily." | 3.74 | Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. ( Coté, GA; Ferreira, MR; Howden, CW; Rozenberg-Ben-Dror, K, 2007) |
| " The aim of this study was to investigate the relationship between the severity of reflux esophagitis and esophageal dysmotility and evaluate the effect of prolonged treatment with proton pump inhibitor (lansoprazole 30 mg/day) on esophageal motility in patients with severe reflux esophagitis associated with esophageal motility disorder." | 3.74 | Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility. ( Hou, XH; Song, GQ; Xie, XP; Xu, JY, 2007) |
| "To assess the acceptability of lansoprazole orally disintegrating tablets (LODT) in patients with gastro-oesophageal reflux disease (GORD)." | 3.74 | Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study. ( de Argila, CM; Galván, J; Heras, J; Márquez, E; Plazas, MJ; Ponce, J; Porcel, J, 2007) |
| "A 57-year-old man developed chronic, watery diarrhea four weeks after Helicobacter pylori eradication therapy including lansoprazole followed by lansoprazole monotherapy for gastroesophageal reflux disease." | 3.73 | Lansoprazole-associated collagenous colitis: a case report. ( Höbling, W; Kirchgatterer, A; Knoflach, P; Rammer, M, 2005) |
| "Helicobacter pylori eradication was recommended for the prevention of atrophic gastritis in gastroesophageal reflux disease (GERD) patients on long-term omeprazole treatment." | 3.73 | Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients. ( Celikel, CA; Giral, A; Kalayci, C; Ozdogan, O; Tözün, N; Ulusoy, NB, 2005) |
| "To compare the efficacy of laparoscopic fundoplication and lansoprazole in abolishing abnormal reflux in patients with gastro-oesophageal reflux disease." | 3.71 | Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison. ( De Micheli, E; Frazzoni, M; Grisendi, A; Lanzani, A; Melotti, G, 2002) |
| " Group 1 consisted of 17 patients with gastroesophageal reflux disease (GERD) taking omeprazole 20 mg b." | 3.70 | Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. ( Bracy, NA; Castell, DO; Katz, PO; Peghini, PL, 1998) |
| "Lansoprazole intolerance requiring omeprazole conversion occurred in 5% of veterans on proton pump inhibitor therapy for chronic gastro-oesophageal reflux disease (GERD) symptoms and in 10% of patients with prior omeprazole success." | 3.70 | Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease. ( Fass, R; Gerson, LB; Hatton, BN; Jones, W; Pulliam, G; Ryono, R; Sampliner, RE; Triadafilopoulos, G, 2000) |
| " The Genotype Tailored Treatment of Symptomatic Acid Reflux in Children with Uncontrolled Asthma (GenARA) study is a randomized, double-blind, placebo-controlled trial to determine if genotype-tailored PPI dosing improves asthma symptoms among children with inadequately controlled asthma and GERD symptoms." | 2.90 | Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods. ( Blake, KV; Cobbaert, M; Fischer, BM; Franciosi, J; Hossain, MJ; Lang, JE; Lima, JJ; Mougey, EB; Schmidt, S; Tang, M, 2019) |
| "Rates of EE recurrence during the 24-wk maintenance period were 16." | 2.87 | Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole. ( Ashida, K; Hiramatsu, N; Hori, T; Iwakiri, K; Kudou, K; Nishimura, A; Sakurai, Y; Umegaki, E, 2018) |
| "Gastroesophageal reflux (GER) is considered a cause of otitis media with effusion (OME)." | 2.87 | A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion. ( Dewan, K; Lieu, J, 2018) |
| "Persistent throat symptoms and Extra Oesophageal Reflux (EOR) are among the commonest reasons for attendance at a secondary care throat or voice clinic." | 2.82 | TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial. ( Carding, P; Fouweather, T; Lecouturier, J; O'Hara, J; Stocken, D; Watson, G; Wilson, J, 2016) |
| "Pantoprazole is a less potent proton pump inhibitor than the other PPIs tested on the first day of treatment." | 2.82 | Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. ( Aydın, D; Çelebi, A; Hülagü, S; Kocaman, O; Konduk, BT; Şentürk, Ö, 2016) |
| "The association of gastroesophageal reflux disease (GERD) and laryngeal symptoms is not clear." | 2.78 | Is the proton pump inhibitor test helpful in patients with laryngeal symptoms? ( Hong, SN; Kim, JH; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2013) |
| "15 healthy Japanese volunteers were dosed for 7 days in a four-way random crossover trial with 100 mg entero-coated type aspirin only once daily, 100 mg aspirin + 20 mg famotidine twice daily, 15 mg lansoprazole once daily, or 10 mg rabeprazole once daily." | 2.77 | Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin. ( Furuta, T; Ikuma, M; Kodaira, C; Nishino, M; Sugimoto, M; Uotani, T; Yamade, M, 2012) |
| "We aimed to examine the proportion of gastroesophageal reflux disease (GERD) in young patients with NCCP compared to the average-aged NCCP patients and to evaluate their symptomatic characteristics and the clinical efficacy of a 2-week proton pump inhibitor (PPI) trial." | 2.77 | Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain. ( Hong, SN; Kim, JH; Kim, SI; Ko, SY; Lee, JH; Lee, KJ; Lee, SY; Park, HS; Shim, CS; Sung, IK, 2012) |
| " lansoprazole 15 mg, dosed before breakfast." | 2.75 | Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors. ( Erasala, GN; Gibb, RD; McKean, LA; McRorie, JW; Miner, PB; Ramsey, DL, 2010) |
| "In this open-label, 3-way crossover study, 83 Hispanics with symptomatic GERD were randomized to 1 of 6 possible treatment sequences of three 5-7-day dosing periods with esomeprazole 40 mg, lansoprazole 30 mg and pantoprazole 40 mg daily separated by 10-17-day washout periods." | 2.75 | Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole. ( Barker, PN; Goldstein, JL; Illueca, M; Katz, PO; Morgan, D; Pandolfino, J, 2010) |
| "Only patients with GERD had significantly (P = 0." | 2.75 | Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy. ( Garrett, CG; Goutte, M; Hagaman, D; Jerome, WG; Slaughter, JC; Smith, BS; Vaezi, MF; Washington, MK, 2010) |
| "Gastroesophageal reflux is common among patients with postnasal drainage." | 2.75 | Proton pump inhibitor therapy improves symptoms in postnasal drainage. ( Allocco, CT; Clement, LE; Duncavage, JA; Goutte, M; Hagaman, DD; Lanza, DC; McCafferty, BA; Slaughter, JC; Sparkman, C; Tanner, SB; Vaezi, MF; Wasden, CM; Wirth, D, 2010) |
| "While proton pump inhibitors are frequently administered in the intensive care unit, the pharmacodynamic response of acid suppression between the enteral and intravenous (IV) route is unknown." | 2.73 | Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients. ( Devlin, JW; Olsen, KM, 2008) |
| "To compare repeated once daily bedtime dosing of IR-OME, lansoprazole and esomeprazole on nocturnal gastric acidity." | 2.73 | Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. ( Bagin, RG; Ballard, ED; Checani, GC; Gautille, TC; Hogan, DL; Katz, PO; Koch, FK; Pratha, VS, 2007) |
| "To determine the level of acid control and the dose-response relationships achieved with esomeprazole and lansoprazole." | 2.73 | Acid control with esomeprazole and lansoprazole: a comparative dose-response study. ( Lind, T; Lundin, C; Nauclér, E; Nilsson-Pieschl, C; Röhss, K; Wilder-Smith, C, 2007) |
| "A new questionnaire for assessing gastroesophageal reflux disease (GERD), the Frequency Scale for Symptoms of GERD, covers the 12 most common symptoms of GERD patients." | 2.73 | Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients. ( Horikoshi, T; Kawamura, O; Kuribayashi, S; Kusano, M; Maeda, M; Moki, F; Mori, M; Nagoshi, A; Shimoyama, Y; Sugimoto, S; Toki, M; Zai, H, 2007) |
| "Mucosal injury caused by gastroesophageal reflux may result in changes in esophageal mucosal blood flow." | 2.73 | Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor. ( Iida, T; Mine, S; Okada, Y; Tabata, T; Tanaka, Y, 2008) |
| "Comparative studies of proton pump inhibitors (PPIs) have revealed that acid reflux is influenced by PPI treatment, formulations and dosing regimens." | 2.73 | Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients. ( Brugnera, R; Calabrese, C; Di Febo, G; Gabusi, V; Gionchetti, P; Liguori, G; Rizzello, F; Straforini, G, 2008) |
| "The diagnosis of GERD was established by the method of Los Angeles classification including mucosal minimum change of Grade M and questionnaire for the diagnosis of reflux disease (QUEST) score." | 2.72 | A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease. ( Dobashi, K; Ishizuka, T; Kawamura, O; Kobayashi, S; Kusano, M; Mori, M; Ohki, I; Shimizu, Y; Shimoyama, Y; Sunaga, N; Tokushima, M; Utsugi, M, 2006) |
| "Pretransplantation, there were no significant differences in the pharmacokinetic parameters of (R)-lansoprazole between the 3 ABCBI C3435T genotypes." | 2.72 | Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus. ( Habuchi, T; Inoue, K; Ishikawa, M; Kagaya, H; Kanno, S; Miura, M; Sagae, Y; Saito, M; Satoh, S; Suzuki, T; Tada, H, 2006) |
| "Management costs for gastroesophageal reflux disease are high because of the expensive medications used for maintenance therapy." | 2.71 | Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. ( Bernard, L; Fendrick, AM; Inadomi, JM; McIntyre, L, 2003) |
| "To compare the effects of standard-dose esomeprazole with those of standard doses of lansoprazole and rabeprazole on intragastric pH during repeated daily oral dosing in healthy volunteers." | 2.71 | Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers. ( Junghard, O; Nilsson-Pieschl, C; Nyman, L; Röhss, K; Wilder-Smith, CH, 2003) |
| "pylori) eradication on gastroesophageal reflux disease is controversial." | 2.71 | The effect of Helicobacter pylori eradication on gastroesophageal reflux disease. ( Güliter, S; Kandilci, U, 2004) |
| " This study was designed to investigate the dosing patterns of patients on on-demand treatment and to compare lansoprazole with omeprazole in this regard." | 2.70 | On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. ( Grove, O; Johnsson, F; Moum, B; Simren, M; Thoring, M; Vilien, M, 2002) |
| " Safety for all study participants was monitored by adverse event reports and laboratory evaluations." | 2.70 | Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. ( Fitzgerald, J; Hassall, E; Huang, B; Kane, R; Pilmer, B; Tolia, V, 2002) |
| "A 24-h gastric pH recording and a pharmacokinetic study were performed after 7 days of lansoprazole, 17 mg/m2, in 23 patients with reflux oesophagitis (median age, 3." | 2.70 | Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis. ( Faure, C; Hankard, R; Jacoz-Aigrain, E; Laurence, M; Michaud, L; Mougenot, JF; Navarro, J; Popon, M; Shaghaghi, EK, 2001) |
| "When lansoprazole 30 mg was given once daily, the mean 24-hour intragastric pH values in the subjects who were homozygous extensive metabolizers, heterozygous extensive metabolizers, and poor metabolizers were 4." | 2.70 | Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. ( Furuta, T; Ishizaki, T; Ohashi, K; Shirai, N; Xiao, F, 2001) |
| "A urea breath test was performed 1 month after the end of therapy; patients and investigators were blind to the results." | 2.70 | Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial. ( Dhir, V; Laine, L, 2002) |
| "Lansoprazole was superior to famotidine in reducing the thickness of esophageal wall." | 2.69 | Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux. ( Aibe, T; Eto, S; Fujisaki, T; Iida, T; Matsuoka, H; Mine, S; Morimoto, I; Tabata, T; Tanaka, Y; Yamada, S, 2000) |
| " Few data exist to compare the ability of the most-often used proton pump inhibitors, omeprazole and lansoprazole, to control gastric acid at twice-daily dosage regimens." | 2.69 | Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole. ( Castell, DO; Hatlebakk, JG; Katz, PO, 2000) |
| "Gastro-oesophageal reflux disease (GERD) can be effectively treated pharmacologically or surgically." | 2.68 | Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland. ( Isolauri, J; Nevalainen, J; Viljakka, M, 1997) |
| "PPIs are not effective in reducing GERD symptoms in infants." | 2.47 | Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review. ( Benninga, MA; Omari, TI; Smits, MJ; Tabbers, MM; van der Pol, RJ; van Wijk, MP, 2011) |
| "Unexplained chest pain is potentially attributable to gastro-oesophageal reflux disease (GORD) or oesophageal motility disorders." | 2.47 | Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease. ( Howden, CW; Hughes, N; Kahrilas, PJ, 2011) |
| " However, the PPI are different according to fast onset and duration of antisecretory action, pH-selectivity, metabolism, interactions with other medicines and dosage forms." | 2.46 | [How to choose correct proton pump inhibitors to patients with GERD?]. ( Bordin, DS, 2010) |
| "Dexlansoprazole was well tolerated compared with placebo or lansoprazole in all studies." | 2.46 | Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system. ( Emerson, CR; Marzella, N, 2010) |
| "Dexlansoprazole DDR has the potential to outperform traditional PPIs based on the metabolism and novel pharmacokinetics." | 2.45 | Dexlansoprazole MR. ( Aslam, N; Wright, R, 2009) |
| "The consequences of nocturnal gastroesophageal reflux disease (GERD) may be greater than daytime GERD in terms of clinical complications such as increased risk of esophageal lesions and respiratory conditions, as well as issues of health-related quality of life, sleep, work productivity, and economics." | 2.44 | Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies. ( Johnson, DA; Katz, PO, 2008) |
| "Lansoprazole is an H+, K+-adenosine triphosphatase proton pump inhibitor (PPI) used for management of acid-related disorders." | 2.43 | Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders. ( Baldi, F, 2005) |
| " For the better PPI-based treatment, doses and dosing schemes of PPIs should be optimized based on CYP2C19 genotype status." | 2.43 | Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. ( Furuta, T; Hishida, A; Ishizaki, T; Nakamura, A; Shirai, N; Sugimoto, M, 2005) |
| "Lansoprazole is a proton pump inhibitor that inactivates the H(+)/K(+)-ATPase pump in parietal cells, thus inhibiting gastric acid secretion and increasing intragastric pH." | 2.43 | Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents. ( Croom, KF; Scott, LJ, 2005) |
| "To review the literature on the treatment of gastroesophageal reflux disease (GERD) with emphasis on pharmacological aspects." | 2.43 | Treatment of gastroesophageal reflux disease. ( Camargos, PA; Guimarães, EV; Marguet, C, 2006) |
| "The length of the Barrett's esophagus segment and the size of a hiatal hernia are associated with the risk of developing high-grade dysplasia and esophageal adenocarcinoma." | 2.42 | Reflux disease and Barrett's esophagus. ( Haag, S; Holtmann, G, 2003) |
| "It has been shown that GERD has a significant impact on patients' quality of life; therefore, improvement of quality of life is one of the major goals of GERD treatment." | 2.42 | The impact of gastroesophageal reflux disease on quality of life. ( Kamolz, T; Pointner, R; Velanovich, V, 2003) |
| "Gastro-oesophageal reflux disease (GORD) is a common, chronic disorder that can progress to erosive or ulcerative oesophagitis and other complications." | 2.42 | Improving health-related quality of life in gastro-oesophageal reflux disease. ( Crawley, JA; Shaw, MJ, 2003) |
| "Gastroesophageal reflux disease (GERD) is a wide spread disease characterized by distinct clinical polymorphism manifesting with various symptoms and/or inflammatory changes of a distal portion of the esophagus." | 2.42 | [Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease]. ( Balashova, NN; Busarova, GA; Maev, IV, 2003) |
| " Multicentre randomised controlled studies are needed to better define the efficacy profile, the optimal dosage with respect to the different indications and the safety profile for chronic therapy of proton pump inhibitors in children." | 2.42 | Proton pump inhibitors in children: a review. ( Gerarduzzi, T; Marchetti, F; Ventura, A, 2003) |
| "Gastro-oesophageal reflux (GOR) and gastro-oesophageal reflux disease (GORD) have a higher prevalence among infants than among children or adults." | 2.42 | Managing gastro-oesophageal reflux disease in children. ( Cezard, JP, 2004) |
| "Lansoprazole was superior to famotidine with regard to both efficacy and cost-effectiveness and therefore is the preferred therapeutic agent for the maintenance treatment of GERD." | 2.42 | [Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist]. ( Habu, Y; Hayakumo, T; Kawai, K; Shio, S; Yoshino, T, 2004) |
| "Initial therapy of GERD should be started with a full dose of PPI." | 2.42 | [PPI: new strategies for GERD]. ( Hoshino, E; Ishiyama, A; Tsuchida, T, 2004) |
| "Gastroesophageal reflux disease (GERD) is among the most common disorders of the gastrointestinal tract, with symptoms affecting a substantial proportion of the US population on a daily basis." | 2.42 | Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor. ( Freston, JW, 2004) |
| " Novel dosage formulations of lansoprazole that may be appropriate for patients with dysphagia include the commercially manufactured lansoprazole strawberry-flavored enteric-coated granules for suspension and lansoprazole orally disintegrating tablets." | 2.42 | Management of acid-related disorders in patients with dysphagia. ( Howden, CW, 2004) |
| "Food and Drug Administration for treatment of gastroesophageal reflux disease: radiofrequency energy delivery to the gastroesophageal junction, and transoral flexible endoscopic suturing." | 2.41 | Gastroesophageal reflux disease: new treatments. ( Katz, PO, 2002) |
| "Studies that appeared to show that GERD could be provoked by antimicrobial therapy of duodenal ulcers also have methodological weaknesses." | 2.41 | Motion--Helicobacter pylori worsens GERD: arguments for the motion. ( O'Morain, CA; Qasim, A, 2002) |
| "Gastroesophageal reflux disease is a complex, multifaceted disorder affecting a large proportion of the US population." | 2.41 | The pharmacology and clinical relevance of proton pump inhibitors. ( Frissora, C; Katz, PO, 2002) |
| " The time of dosing and ingestion of meals may also influence the pharmacokinetics of these agents as well as their ability to suppress gastric acid secretion." | 2.41 | Shortcomings of the first-generation proton pump inhibitors. ( Tytgat, GN, 2001) |
| "Lansoprazole is a proton pump inhibitor that reduces gastric acid secretion in a dose-dependent manner via inhibition of H+/K+-adenosine triphosphatase in gastric parietal cells." | 2.41 | An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole. ( Bown, RL, 2002) |
| "Although gastroesophageal reflux disease (GERD) is believed to be primarily a motor disorder, current medical therapy is based on the inhibition of acid secretion, since it is the deleterious effects of the acidic refluxate that lead to the symptoms and complications of GERD." | 2.40 | Long-term management of gastroesophageal reflux disease and its complications. ( Richter, JE, 1997) |
| "Gastroesophageal reflux disease results from excessive exposure of the oesophagus to acidic contents." | 2.40 | Acid pump inhibitors. The treatment of gastroesophageal reflux. ( Hetzel, D, 1998) |
| "Although relatively rare, GERD patients refractory to medical therapy remain a challenge for the clinician." | 2.40 | Medical therapy. Management of the refractory patient. ( Castell, DO; Hatlebakk, JG; Katz, PO, 1999) |
| " The ideal therapy for GORD will have linear pharmacokinetics, a relatively long plasma half-life (t1/2), a duration of action allowing once daily administration, and a stable effect independent of interactions with food, antacids and other drugs." | 2.39 | Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. ( Berstad, A; Hatlebakk, JG, 1996) |
| "Reflux esophagitis is a chronic condition and after stopping antisecretory treatment, including lansoprazole, most patients relapse in terms of symptoms and endoscopical lesions, which suggests the need for long-term treatment." | 2.38 | Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview. ( Di Fede, F; Dobrilla, G, 1993) |
| "There is no curative treatment for gastroesophageal reflux disease." | 1.91 | The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment. ( Aktan, Ç; Balcan, E; Buran, T; Kasap, E; Korkmaz, M; Solmaz Hasdemir, P; Toraman Avcu, A, 2023) |
| "Objective Gastroesophageal reflux disease (GERD) is a highly prevalent disorder that negatively affects patients' quality of life and reduces their work productivity." | 1.51 | Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan. ( Habu, Y, 2019) |
| "Patients with COPD in groups C and D in the stable phase were stratified into a group with neither gastroesophageal reflux nor lansoprazole therapy (group A) and a group subjected to oral lansoprazole therapy (group B1 ) and a group not subjected to oral lansoprazole therapy (group B2 )." | 1.43 | A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease. ( Ding, W; Liu, JM; Xiong, W; Zhang, QS; Zhao, W; Zhao, YF, 2016) |
| "Despite GERD being a chronic disease in most patients, there was a high degree of alteration seen in the utilization patterns of PPIs." | 1.39 | Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. ( Hatlebakk, JG; Jonasson, C; Tvete, IF, 2013) |
| " Rates of congenital malformations in PPIs exposed and unexposed pregnancies, as well as other adverse fetal effects were compared." | 1.38 | The safety of fetal exposure to proton-pump inhibitors during pregnancy. ( Gorodischer, R; Koren, G; Levy, A; Matok, I; Uziel, E; Wiznitzer, A, 2012) |
| "Methylphenidate was the top prescription dispensed to adolescents (aged 12-17 years)." | 1.38 | Trends of outpatient prescription drug utilization in US children, 2002-2010. ( Chai, G; Governale, L; McMahon, AW; Murphy, D; Staffa, J; Trinidad, JP, 2012) |
| "In our study of 154 GERD patients, 50 received omeprazole, 51 - lansoprazole and 53 - pantoprazole in a standard daily dose." | 1.38 | [Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors]. ( , 2012) |
| "nonwhite patients with gastro-oesophageal reflux disease (GERD)." | 1.37 | Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors. ( Illueca, M; Johnson, DA; Monyak, JT; Sharma, P, 2011) |
| "Gastro-esophageal reflux disease (GERD) is a chronic condition, with 50-80% of patients experiencing recurrence within one year following completion of initial treatment." | 1.36 | [Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients]. ( Choi, TH; Hwang, JH; Hwang, TJ; Jeong, SH; Jeong, YJ; Jung, HC; Kim, JW; Kim, N; Lee, BH; Lee, DH; Lee, SH; Nah, JC; Park, YS; Song, IS, 2010) |
| "Forty-five patients with suspected gastroesophageal reflux diseases related symptoms (sore throat, throat burning, throat clearing, globus sensation, cough, halitozis, dysphonia, dysphagia, postnasal dripping, vocal fatigue, and sputum) were included in this study." | 1.35 | Association of laryngopharyngeal manifestations and gastroesophageal reflux. ( Akkaynak, C; Naiboglu, B; Ozel, L; Toros, AB; Toros, SZ; Yüksel, OD, 2009) |
| "Dexlansoprazole MR is a novel Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to prolong the plasma concentration-time profile of dexlansoprazole and extend duration of acid suppression with once-daily (QD) dosing." | 1.35 | Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. ( Atkinson, SN; Mulford, D; Vakily, M; Wu, J; Zhang, W, 2009) |
| "Maintenance therapy of gastroesophageal reflux disease (GERD) is usually performed with a low dose of a proton-pump inhibitor (PPI)." | 1.35 | CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. ( Furuta, T; Hishida, A; Ikuma, M; Kimura, M; Kodaira, C; Nishino, M; Shirai, N; Sugimoto, M; Umemura, K; Watanabe, H; Yamade, M, 2009) |
| "Dexlansoprazole MR is a dual delayed release formulation of dexlansoprazole, an enantiomer of lansoprazole." | 1.35 | Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. ( Atkinson, SN; Dabholkar, AH; Metz, DC; Paris, MM; Peura, DA; Yu, P, 2009) |
| "The on-demand dosing regimen generated a wide range of drug exposure." | 1.35 | Linear and loglinear structural mean models to evaluate the benefits of an on-demand dosing regimen. ( Baxter, G; Comté, L; Tousset, E; Vansteelandt, S; Vrijens, B, 2009) |
| "The causes of syncope are diverse and may manifest in disorders of different organ systems in the body." | 1.35 | Cough syncope induced by gastroesophageal reflux disease. ( Iida, H; Kanazawa, Y; Kino, N; Kusuyama, T; Shimodozono, S, 2009) |
| "Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux." | 1.34 | Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy. ( Goh, KL; Gopala, K; Qua, CS; Wong, CH, 2007) |
| "Omeprazole was used in 90% of the patients; lansoprazole, in 7%." | 1.34 | Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. ( El-Serag, HB; Hassall, E; Kerr, W, 2007) |
| "Gastroesophageal reflux disease (GERD) influences the symptoms of asthma with acid and oxidative stress." | 1.34 | Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. ( Dobashi, K; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Ono, A; Shimizu, Y; Utsugi, M; Yanagitani, N; Zhao, JJ, 2007) |
| "Chronic cough is defined as that which is persisting at least for trhee weeks without an evident cause." | 1.34 | [Otorhinolaringologyc approach of the chronic cough. Clinical case]. ( García de Hombre, AM, 2007) |
| "It was shown that gastroesophageal reflux disease was one of the possible causes of eosinophilia." | 1.34 | [A case of gastroesophageal reflux disease with marked eosinophilia]. ( Inoue, T; Inui, Y; Katata, T; Kizu, T; Kohro, T; Matsumoto, Y; Miyoshi, R; Nishikawa, M; Watanabe, C; Yasunaga, Y, 2007) |
| "Lansoprazole was superior to ranitidine with regard to both efficacy and cost-effectiveness and therefore is the preferred therapeutic agent for treatment of NERD." | 1.34 | [Cost-effectiveness analysis for the treatment of non-erosive reflux disease]. ( Fukui, Y; Habu, Y; Hisatsune, H; Kawai, K; Maruno, T, 2007) |
| " Medical charts were reviewed in a subset of patients to gather dosing information." | 1.34 | Proton pump inhibitor utilization patterns in infants. ( Bakst, AW; Barron, JJ; Singer, J; Spalding, J; Tan, H, 2007) |
| "Laryngopharyngeal reflux (LPR) is frequently treated with empiric proton-pump inhibitors (PPI), but the optimal dosing and duration is unknown." | 1.33 | Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. ( Abelson, TI; Hicks, DM; Khandwala, F; Milstein, C; Park, W; Richter, JE; Vaezi, MF, 2005) |
| "The article covers the modem concept of gastroesophageal reflux disease (GERD) pharmacogenomics." | 1.33 | [Pharmacogenomical aspects of gastroesophageal reflux disease]. ( Isaev, VA, 2005) |
| "Gastroesophageal reflux disease (GERD) is commonly associated with asthma; however, frequency in nonatopic children with asthmatic symptoms is unknown." | 1.33 | Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease. ( Aydoğdu, S; Kasirga, E; Kirmaz, C; Yilmaz, O; Yüksel, H, 2006) |
| " Long-term dosing schedule (high dose or step-down dose) was based on current market data." | 1.33 | Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK. ( Brown, RE; Remák, E; Robinson, A; Yuen, C, 2005) |
| "The causal association between gastro-oesophageal reflux disease (GERD) and difficult-to-control asthma is unclear." | 1.33 | Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy. ( Chua, CJ; Goh, KL; Liam, CK; Wong, CH, 2006) |
| " Pre-meal dosing maximizes efficacy while sub-optimal dose timing may limit efficacy." | 1.33 | Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease. ( Gunaratnam, NT; Inadomi, J; Jessup, TP; Lascewski, DP, 2006) |
| "Cough was significantly less severe in NEE adolescents than in younger children." | 1.33 | Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. ( Amer, F; Chiu, YL; Gupta, SK; Hassall, E; Heyman, MB, 2006) |
| "In most patients with GERD esophagitis is not detected by endoscopy, which represents GERD with a negative endoscopy or non-erosive reflux disease (NERD)." | 1.33 | Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori. ( Castro Fernández, M; García Díaz, E; Lamas Rojas, E; Larraona, JL; Núñez Hospital, D; Pallarés Querol, M; Rodríguez Hornillo, MC, 2006) |
| "The cough was eliminated or markedly improved in 38 patients (86%) after 4 weeks and by 8 weeks in the remaining 6 patients." | 1.32 | Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment. ( Kallay, MC; Poe, RH, 2003) |
| "Gastroesophageal reflux disease (GERD), is a common disorder." | 1.32 | Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions. ( Kivioja, A; Linnosmaa, I; Vehviläinen, A; Vohlonen, I, 2004) |
| "In refractory cases of GERD, eosinophilic esophagitis must be considered before any surgical measure." | 1.32 | Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice. ( Cury, EK; Faintuch, S; Schraibman, V, 2004) |
| "Thirty-two patients with long-segment Barrett esophagus who were asymptomatic with PPIs." | 1.32 | Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy. ( Casey, JF; Clark, GW; Guillou, PJ; Hick, DG; Sarela, AI; Verbeke, CS, 2004) |
| "Some patients with gastro-oesophageal reflux disease continue to experience symptoms despite therapy with proton pump inhibitors." | 1.31 | An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy. ( Murray, JA; Nzeako, UC, 2002) |
| "Rabeprazole subjects had lower GERD-related costs, less escalation, and lower DACON (measured as number of tablets consumed per day), compared to lansoprazole and omeprazole subjects." | 1.31 | Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs. ( Dodd, S; Durkin, M; Hall, J; Sloan, S, 2002) |
| "A total of 65 patients with GERD (grades A-D) completed treatment with lansoprazole, by taking 30 mg orally once a day for 8 weeks." | 1.31 | Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. ( Furuta, T; Futami, H; Hanai, H; Honda, S; Iida, T; Ishizaki, T; Kajimura, M; Ohashi, K; Sato, Y; Shirai, N; Takayanagi, S; Takeuchi, K; Watanabe, F; Yamada, M, 2002) |
| "In gastro-oesophageal reflux disease (GORD), the majority of patients are endoscopy negative." | 1.31 | How do we offer clinical relief to patients with gastro-oesophageal reflux disease? ( Galmiche, JP, 2000) |
| "In the dysphagia group, 48 of 54 patients (89%) had edema of the posterior larynx, and 42 of 54 (78%) had laryngopharyngeal sensory deficits." | 1.31 | Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia. ( Aviv, JE; Close, LG; Kaplan, ST; Liu, H; Parides, M, 2000) |
| "Gastroesophageal reflux, common in infants, usually resolves spontaneously by 12 to 18 months." | 1.31 | [Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials]. ( Niimi, S; Saigusa, H; Saigusa, U; Yagi, T, 2001) |
| "All 8 patients had initial control of laryngospasm." | 1.31 | Laryngospasm: an atypical manifestation of severe gastroesophageal reflux disease (GERD). ( Maceri, DR; Zim, S, 2001) |
| "Lansoprazole was mostly prescribed in patients with reflux oesophagitis (55." | 1.30 | A prospective follow-up study of 5669 users of lansoprazole in daily practice. ( Claessens, A; Heerdink, E; Lamers, CB; Leufkens, H; van Eijk, J, 1997) |
| " The two groups were not different in regard to their symptom frequency and severity before therapy, amount of lansoprazole dosage required to eliminate symptoms, length of Barrett's metaplasia, presence of hiatal hernia, lower esophageal sphincter resting tone and length, or esophageal peristaltic function." | 1.30 | Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus. ( Ouatu-Lascar, R; Triadafilopoulos, G, 1998) |
| "A total of 172 symptomatic GERD patients completed a 57-item questionnaire (containing the SF-12; symptom frequency/bothersomeness; problems related to activities, sleep, work disability; overall HRQoL; and treatment satisfaction) at baseline, week 1 [retest (N = 25)], and week 4 [follow-up (N = 100)]." | 1.30 | Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study. ( Colwell, HH; Henning, JM; Hunt, RH; Mathias, SD; Pasta, DJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 29 (9.42) | 18.2507 |
| 2000's | 194 (62.99) | 29.6817 |
| 2010's | 78 (25.32) | 24.3611 |
| 2020's | 7 (2.27) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, KS | 1 |
| Shah, AK | 1 |
| Bariwal, J | 1 |
| Shelke, SM | 1 |
| Kale, AP | 1 |
| Jagtap, JR | 1 |
| Bhosale, AV | 1 |
| Zhao, H | 1 |
| Li, Y | 1 |
| Jayasekara, R | 1 |
| Smith, I | 1 |
| Kasap, E | 1 |
| Buran, T | 1 |
| Toraman Avcu, A | 1 |
| Solmaz Hasdemir, P | 1 |
| Balcan, E | 1 |
| Aktan, Ç | 1 |
| Korkmaz, M | 1 |
| Sharif, A | 1 |
| Carr, L | 1 |
| Saliakellis, E | 1 |
| Chakraborty, H | 1 |
| Lin, XH | 1 |
| Luo, JC | 1 |
| Ting, PH | 1 |
| Chang, TE | 1 |
| Huang, YH | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Scarpignato, C | 2 |
| Hongo, M | 1 |
| Wu, JCY | 1 |
| Lottrup, C | 1 |
| Lazarescu, A | 1 |
| Stein, E | 1 |
| Hunt, RH | 3 |
| O'Hara, J | 2 |
| Stocken, DD | 1 |
| Watson, GC | 1 |
| Fouweather, T | 2 |
| McGlashan, J | 1 |
| MacKenzie, K | 1 |
| Carding, P | 2 |
| Karagama, Y | 1 |
| Wood, R | 1 |
| Wilson, JA | 1 |
| Lu, B | 1 |
| Zhang, L | 1 |
| Wang, J | 1 |
| Wang, B | 1 |
| Zou, X | 1 |
| Fei, G | 1 |
| Chen, D | 1 |
| Wang, X | 1 |
| Wu, B | 1 |
| Zou, D | 1 |
| Ashida, K | 1 |
| Iwakiri, K | 2 |
| Hiramatsu, N | 1 |
| Sakurai, Y | 1 |
| Hori, T | 1 |
| Kudou, K | 1 |
| Nishimura, A | 1 |
| Umegaki, E | 1 |
| Dewan, K | 1 |
| Lieu, J | 1 |
| Oshima, T | 2 |
| Arai, E | 1 |
| Taki, M | 1 |
| Kondo, T | 1 |
| Tomita, T | 1 |
| Fukui, H | 1 |
| Watari, J | 1 |
| Miwa, H | 6 |
| Tang, M | 1 |
| Blake, KV | 1 |
| Lima, JJ | 5 |
| Mougey, EB | 2 |
| Franciosi, J | 1 |
| Schmidt, S | 1 |
| Hossain, MJ | 1 |
| Cobbaert, M | 1 |
| Fischer, BM | 1 |
| Lang, JE | 3 |
| Righini Grunder, F | 1 |
| Petit, LM | 1 |
| Ezri, J | 1 |
| Jantchou, P | 1 |
| Aspirot, A | 1 |
| Laberge, S | 1 |
| Faure, C | 2 |
| Habu, Y | 3 |
| Kim, JH | 2 |
| Sung, IK | 2 |
| Hong, SN | 2 |
| Lee, SY | 2 |
| Park, HS | 2 |
| Shim, CS | 2 |
| Peura, DA | 6 |
| Pilmer, B | 4 |
| Hunt, B | 3 |
| Mody, R | 4 |
| Perez, MC | 6 |
| Kinoshita, Y | 7 |
| Sanada, K | 4 |
| Miyata, K | 2 |
| Haruma, K | 5 |
| Giral, A | 2 |
| Kurt, R | 1 |
| Yeğin, EG | 1 |
| Yeğin, K | 1 |
| Ghebremariam, YT | 2 |
| LePendu, P | 1 |
| Lee, JC | 1 |
| Erlanson, DA | 1 |
| Slaviero, A | 1 |
| Shah, NH | 1 |
| Leiper, J | 1 |
| Cooke, JP | 2 |
| Jonasson, C | 1 |
| Tvete, IF | 1 |
| Hatlebakk, JG | 5 |
| Turhan Iyidir, O | 1 |
| Cimen, AR | 1 |
| Değertekin, CK | 1 |
| Baloş Törüner, F | 1 |
| Cakır, N | 1 |
| Arslan, M | 1 |
| Uygun, I | 1 |
| Arslan, MS | 1 |
| Aydogdu, B | 1 |
| Okur, MH | 1 |
| Otcu, S | 1 |
| Savarino, E | 1 |
| De Cassan, C | 1 |
| Bodini, G | 1 |
| Furnari, M | 1 |
| de Bortoli, N | 1 |
| Savarino, V | 6 |
| Yamamoto, E | 1 |
| Brito, HS | 1 |
| Ogata, SK | 1 |
| Machado, RS | 1 |
| Kawakami, E | 1 |
| Franciosi, JP | 1 |
| Sakamoto, S | 2 |
| Hiroi, S | 2 |
| Holbrook, JT | 3 |
| Wei, CY | 1 |
| Wise, RA | 2 |
| Teague, WG | 2 |
| Sukhovershin, RA | 1 |
| Lopez, JL | 1 |
| Tayek, JA | 1 |
| Alkeraye, S | 1 |
| Baclet, Y | 1 |
| Delaporte, E | 1 |
| Watson, G | 1 |
| Lecouturier, J | 1 |
| Stocken, D | 1 |
| Wilson, J | 1 |
| Xiong, W | 1 |
| Zhang, QS | 1 |
| Zhao, W | 1 |
| Ding, W | 1 |
| Liu, JM | 1 |
| Zhao, YF | 1 |
| Takenaka, R | 1 |
| Okada, H | 1 |
| Kawano, S | 1 |
| Komazawa, Y | 3 |
| Yoshinaga, F | 1 |
| Nagata, S | 1 |
| Inoue, M | 2 |
| Komatsu, H | 1 |
| Onogawa, S | 1 |
| Kushiyama, Y | 1 |
| Mukai, S | 1 |
| Todo, H | 1 |
| Okanobu, H | 1 |
| Manabe, N | 1 |
| Tanaka, S | 1 |
| Çelebi, A | 1 |
| Aydın, D | 1 |
| Kocaman, O | 1 |
| Konduk, BT | 1 |
| Şentürk, Ö | 1 |
| Hülagü, S | 1 |
| Umeno, J | 1 |
| Matsumoto, T | 1 |
| Nakamura, S | 1 |
| Jo, Y | 1 |
| Yada, S | 1 |
| Hirakawa, K | 1 |
| Yoshimura, R | 1 |
| Yamagata, H | 1 |
| Kudo, T | 1 |
| Hirano, A | 1 |
| Gushima, M | 1 |
| Yao, T | 1 |
| Nakashima, Y | 1 |
| Iida, M | 1 |
| Springer, M | 1 |
| Atkinson, S | 4 |
| North, J | 2 |
| Raanan, M | 2 |
| Zhang, W | 3 |
| Kukulka, M | 2 |
| Witt, G | 1 |
| Sutkowski-Markmann, D | 1 |
| Chatterjee, S | 1 |
| Johnson, DA | 5 |
| Katz, PO | 14 |
| Toros, SZ | 2 |
| Toros, AB | 1 |
| Yüksel, OD | 1 |
| Ozel, L | 1 |
| Akkaynak, C | 1 |
| Naiboglu, B | 2 |
| Howden, CW | 5 |
| Ballard, ED | 3 |
| Koch, FK | 2 |
| Gautille, TC | 2 |
| Bagin, RG | 2 |
| Tafuri, G | 1 |
| Trotta, F | 1 |
| Leufkens, HG | 1 |
| Martini, N | 1 |
| Sagliocca, L | 1 |
| Traversa, G | 1 |
| Orenstein, SR | 1 |
| Hassall, E | 4 |
| Furmaga-Jablonska, W | 1 |
| Olsen, KM | 1 |
| Devlin, JW | 1 |
| Bordin, DS | 3 |
| Masharova, AA | 2 |
| Arand, M | 1 |
| Vakily, M | 1 |
| Wu, J | 2 |
| Atkinson, SN | 3 |
| Mulford, D | 1 |
| Zheng, RN | 1 |
| Furuta, T | 7 |
| Sugimoto, M | 4 |
| Kodaira, C | 2 |
| Nishino, M | 2 |
| Yamade, M | 2 |
| Ikuma, M | 2 |
| Shirai, N | 5 |
| Watanabe, H | 1 |
| Umemura, K | 1 |
| Kimura, M | 1 |
| Hishida, A | 2 |
| Pellicano, R | 1 |
| Putnam, PE | 1 |
| Barney, CK | 1 |
| Baer, VL | 1 |
| Scoffield, SH | 1 |
| Lambert, DK | 1 |
| Cook, M | 1 |
| Christensen, RD | 1 |
| Blanco, MA | 1 |
| Prieto, M | 1 |
| Mearin, F | 1 |
| Plazas, MJ | 3 |
| Armengol, S | 1 |
| Heras, J | 3 |
| Mas, M | 1 |
| Piqué, JM | 1 |
| Haber, MM | 1 |
| Aslam, N | 1 |
| Wright, R | 1 |
| Metz, DC | 1 |
| Dabholkar, AH | 2 |
| Paris, MM | 2 |
| Yu, P | 1 |
| Comté, L | 1 |
| Vansteelandt, S | 1 |
| Tousset, E | 1 |
| Baxter, G | 1 |
| Vrijens, B | 1 |
| Molloy, D | 1 |
| Molloy, A | 1 |
| O'Loughlin, C | 1 |
| Falconer, M | 1 |
| Hennessy, M | 1 |
| Kusuyama, T | 1 |
| Iida, H | 1 |
| Kino, N | 1 |
| Shimodozono, S | 1 |
| Kanazawa, Y | 1 |
| Osipenko, MF | 1 |
| Bikbulatova, EA | 1 |
| Shakalite, IuD | 1 |
| Nomura, E | 1 |
| Kagaya, H | 2 |
| Uchimi, K | 1 |
| Noguchi, T | 1 |
| Suzuki, S | 1 |
| Suzuki, M | 1 |
| Onodera, H | 1 |
| Tateno, H | 1 |
| Miner, PB | 1 |
| McKean, LA | 1 |
| Gibb, RD | 1 |
| Erasala, GN | 1 |
| Ramsey, DL | 1 |
| McRorie, JW | 1 |
| Jeong, YJ | 1 |
| Lee, DH | 1 |
| Choi, TH | 1 |
| Hwang, TJ | 1 |
| Lee, BH | 1 |
| Nah, JC | 1 |
| Lee, SH | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Kim, JW | 1 |
| Jeong, SH | 1 |
| Kim, N | 1 |
| Jung, HC | 1 |
| Song, IS | 1 |
| Cho, YK | 1 |
| Choi, MG | 1 |
| Lim, CH | 1 |
| Nam, KW | 1 |
| Chang, JH | 1 |
| Park, JM | 1 |
| Lee, IS | 1 |
| Kim, SW | 1 |
| Choi, KY | 1 |
| Chung, IS | 1 |
| Yoshida, N | 1 |
| Kamada, K | 1 |
| Tomatsuri, N | 1 |
| Suzuki, T | 3 |
| Takagi, T | 1 |
| Ichikawa, H | 1 |
| Yoshikawa, T | 1 |
| Abel, C | 1 |
| Desilets, AR | 1 |
| Willett, K | 1 |
| Davies, SL | 1 |
| Morgan, D | 1 |
| Pandolfino, J | 1 |
| Goldstein, JL | 1 |
| Barker, PN | 1 |
| Illueca, M | 2 |
| Talwar, V | 1 |
| Wurm, P | 1 |
| Bankart, MJ | 1 |
| Gershlick, AH | 1 |
| de Caestecker, JS | 1 |
| Croxtall, JD | 1 |
| Scott, LJ | 3 |
| Vaezi, MF | 3 |
| Slaughter, JC | 2 |
| Smith, BS | 1 |
| Washington, MK | 1 |
| Jerome, WG | 1 |
| Garrett, CG | 1 |
| Hagaman, D | 1 |
| Goutte, M | 2 |
| Hagaman, DD | 1 |
| Tanner, SB | 1 |
| Duncavage, JA | 1 |
| Allocco, CT | 1 |
| Sparkman, C | 1 |
| Clement, LE | 1 |
| Wasden, CM | 1 |
| Wirth, D | 1 |
| McCafferty, BA | 1 |
| Lanza, DC | 1 |
| Lee, JH | 2 |
| Kim, MJ | 1 |
| Lee, JS | 1 |
| Choe, YH | 1 |
| Sachs, G | 1 |
| Shin, JM | 1 |
| Hunt, R | 2 |
| Emerson, CR | 1 |
| Marzella, N | 1 |
| Lazebnik, LB | 1 |
| V'iuchnova, ES | 1 |
| Zakharova, NV | 1 |
| Abdulkhakov, RA | 1 |
| Prokhorova, LV | 1 |
| Nikolaeva, NN | 1 |
| Han, C | 4 |
| Eren, M | 1 |
| Yıldırım, SH | 1 |
| Sivrikoz, IA | 1 |
| Fass, R | 7 |
| Orr, WC | 1 |
| Stern, KN | 1 |
| Pilmer, BL | 1 |
| Durmus, R | 1 |
| Tek, A | 1 |
| Egeli, E | 1 |
| Hershcovici, T | 1 |
| Jha, LK | 1 |
| van der Pol, RJ | 1 |
| Smits, MJ | 1 |
| van Wijk, MP | 1 |
| Omari, TI | 1 |
| Tabbers, MM | 1 |
| Benninga, MA | 1 |
| Kahrilas, PJ | 2 |
| Hughes, N | 1 |
| Sharma, P | 2 |
| Monyak, JT | 1 |
| Garza, JM | 1 |
| Nylund, CM | 1 |
| Kaul, A | 1 |
| Behm, BW | 1 |
| Asajima, H | 1 |
| Saito, N | 1 |
| Ohmura, Y | 1 |
| Ohmura, K | 1 |
| Yurtsever, AS | 1 |
| Pektas, M | 1 |
| Ozkur, M | 1 |
| Un, I | 1 |
| Erenmemisoglu, A | 1 |
| Buyukafsar, K | 1 |
| Matok, I | 1 |
| Levy, A | 1 |
| Wiznitzer, A | 1 |
| Uziel, E | 1 |
| Koren, G | 1 |
| Gorodischer, R | 1 |
| Jianu, CS | 1 |
| Lange, OJ | 1 |
| Viset, T | 1 |
| Qvigstad, G | 1 |
| Martinsen, TC | 1 |
| Fougner, R | 1 |
| Kleveland, PM | 1 |
| Fossmark, R | 2 |
| Hauso, Ø | 1 |
| Waldum, HL | 2 |
| Uotani, T | 1 |
| Inadomi, J | 2 |
| O'Neil, J | 1 |
| Gold, BD | 2 |
| Blake, K | 1 |
| Brown, ED | 1 |
| Castro, M | 1 |
| Dozor, AJ | 1 |
| Mastronarde, JG | 1 |
| Sockrider, MM | 1 |
| Adachi, K | 2 |
| Furuta, K | 2 |
| Miki, M | 1 |
| Koike, T | 3 |
| Shimatani, T | 1 |
| Ko, SY | 1 |
| Kim, SI | 1 |
| Lee, KJ | 1 |
| Block, SL | 1 |
| Chai, G | 1 |
| Governale, L | 1 |
| McMahon, AW | 1 |
| Trinidad, JP | 1 |
| Staffa, J | 1 |
| Murphy, D | 1 |
| Hata, S | 1 |
| Arai, M | 1 |
| Maruoka, D | 1 |
| Tanaka, T | 1 |
| Matsumura, T | 1 |
| Nakagawa, T | 1 |
| Katsuno, T | 1 |
| Imazeki, F | 1 |
| Yokosuka, O | 1 |
| Tham, SY | 1 |
| Rogers, IM | 1 |
| Samuel, KF | 1 |
| Singh, A | 1 |
| Ong, KK | 1 |
| Miyashita, T | 1 |
| Shah, FA | 1 |
| Harmon, JW | 1 |
| Marti, GP | 1 |
| Matsui, D | 1 |
| Okamoto, K | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Oyama, K | 1 |
| Nakagawara, H | 1 |
| Tajima, H | 1 |
| Fujita, H | 1 |
| Takamura, H | 1 |
| Murakami, M | 1 |
| Ninomiya, I | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Ohta, T | 1 |
| Alai, M | 1 |
| Lin, WJ | 1 |
| Johnsson, F | 1 |
| Moum, B | 1 |
| Vilien, M | 1 |
| Grove, O | 1 |
| Simren, M | 1 |
| Thoring, M | 1 |
| Nzeako, UC | 1 |
| Murray, JA | 1 |
| Vanderhoff, BT | 1 |
| Tahboub, RM | 1 |
| Hall, J | 1 |
| Dodd, S | 1 |
| Durkin, M | 1 |
| Sloan, S | 1 |
| Nyrén, O | 1 |
| O'Morain, CA | 1 |
| Qasim, A | 1 |
| McColl, KE | 1 |
| Watanabe, F | 1 |
| Honda, S | 1 |
| Takeuchi, K | 1 |
| Iida, T | 4 |
| Sato, Y | 1 |
| Kajimura, M | 1 |
| Futami, H | 1 |
| Takayanagi, S | 1 |
| Yamada, M | 1 |
| Ohashi, K | 2 |
| Ishizaki, T | 4 |
| Hanai, H | 1 |
| Frissora, C | 1 |
| Frazzoni, M | 5 |
| De Micheli, E | 5 |
| Grisendi, A | 4 |
| Haag, S | 1 |
| Holtmann, G | 1 |
| Lauritsen, K | 1 |
| Devière, J | 1 |
| Bigard, MA | 3 |
| Bayerdörffer, E | 1 |
| Mózsik, G | 1 |
| Murray, F | 1 |
| Kristjánsdóttir, S | 1 |
| Vetvik, K | 1 |
| De Freitas, D | 1 |
| Orive, V | 1 |
| Rodrigo, L | 1 |
| Fried, M | 2 |
| Morris, J | 1 |
| Schneider, H | 1 |
| Eklund, S | 1 |
| Larkö, A | 1 |
| Xia, HH | 2 |
| Lai, KC | 2 |
| Lam, SK | 2 |
| Hu, WH | 2 |
| Wong, NY | 2 |
| Hui, WM | 2 |
| Lau, CP | 1 |
| Chen, WH | 1 |
| Chan, CK | 1 |
| Wong, WM | 2 |
| Wong, BC | 2 |
| Tolia, V | 4 |
| Fitzgerald, J | 2 |
| Huang, B | 7 |
| Kane, R | 1 |
| Ferry, G | 1 |
| Gunasekaran, T | 3 |
| Keith, R | 2 |
| Book, L | 2 |
| Gupta, S | 1 |
| Gremse, D | 3 |
| Karol, M | 2 |
| Pan, WJ | 2 |
| Chiu, YL | 4 |
| Winter, H | 1 |
| Poe, RH | 1 |
| Kallay, MC | 1 |
| O'Leary, C | 1 |
| McCarthy, J | 1 |
| Humphries, M | 1 |
| Shanahan, F | 1 |
| Quigley, E | 1 |
| Kawamura, M | 2 |
| Ohara, S | 2 |
| Iijima, K | 2 |
| Suzuki, J | 1 |
| Kayaba, S | 2 |
| Noguchi, K | 2 |
| Hamada, S | 1 |
| Noguchi, M | 2 |
| Shimosegawa, T | 2 |
| Pohland, CJ | 1 |
| Scavnicky, SA | 1 |
| Lasky, SS | 1 |
| Good, CB | 1 |
| Kamolz, T | 1 |
| Pointner, R | 1 |
| Velanovich, V | 1 |
| Bilgen, C | 1 |
| Ogüt, F | 1 |
| Kesimli-Dinç, H | 1 |
| Kirazli, T | 1 |
| Bor, S | 1 |
| Hellström, PM | 1 |
| Vitols, S | 1 |
| Inadomi, JM | 2 |
| McIntyre, L | 1 |
| Bernard, L | 1 |
| Fendrick, AM | 1 |
| Shaw, MJ | 1 |
| Crawley, JA | 1 |
| Maev, IV | 1 |
| Balashova, NN | 1 |
| Busarova, GA | 1 |
| Marchetti, F | 1 |
| Gerarduzzi, T | 1 |
| Ventura, A | 1 |
| Borjesson, M | 1 |
| Rolny, P | 1 |
| Mannheimer, C | 1 |
| Pilhall, M | 1 |
| Miner, P | 1 |
| Chen, Y | 1 |
| Sostek, M | 1 |
| Wilder-Smith, CH | 1 |
| Röhss, K | 3 |
| Nilsson-Pieschl, C | 2 |
| Junghard, O | 1 |
| Nyman, L | 1 |
| Juul-Hansen, P | 3 |
| Rydning, A | 4 |
| Kivioja, A | 1 |
| Linnosmaa, I | 1 |
| Vehviläinen, A | 1 |
| Vohlonen, I | 1 |
| Lam, KF | 1 |
| Huang, JQ | 1 |
| Lam, CL | 1 |
| Chan, AO | 1 |
| Cury, EK | 1 |
| Schraibman, V | 1 |
| Faintuch, S | 1 |
| Cezard, JP | 1 |
| Sarela, AI | 1 |
| Hick, DG | 1 |
| Verbeke, CS | 1 |
| Casey, JF | 1 |
| Guillou, PJ | 1 |
| Clark, GW | 1 |
| Bautista, J | 1 |
| Fullerton, H | 1 |
| Briseno, M | 1 |
| Cui, H | 1 |
| Takeda, H | 1 |
| Yoshino, T | 1 |
| Shio, S | 1 |
| Hayakumo, T | 1 |
| Kawai, K | 2 |
| Hoshino, E | 1 |
| Ishiyama, A | 1 |
| Tsuchida, T | 1 |
| Lind, T | 2 |
| Wilder-Smith, C | 2 |
| Tsai, HH | 1 |
| Chapman, R | 1 |
| Shepherd, A | 1 |
| McKeith, D | 1 |
| Anderson, M | 1 |
| Vearer, D | 1 |
| Duggan, S | 1 |
| Rosen, JP | 1 |
| Güliter, S | 1 |
| Kandilci, U | 1 |
| Hill, RK | 1 |
| Simpson, CB | 1 |
| Velazquez, R | 1 |
| Larson, N | 1 |
| Freston, JW | 2 |
| Sawabata, N | 1 |
| Maeda, H | 1 |
| Takeda, S | 1 |
| Koma, M | 1 |
| Tokunaga, T | 1 |
| Matsuda, H | 1 |
| Johnsen, G | 1 |
| Johanessen, E | 1 |
| Diav-Citrin, O | 1 |
| Arnon, J | 1 |
| Shechtman, S | 1 |
| Schaefer, C | 1 |
| van Tonningen, MR | 1 |
| Clementi, M | 1 |
| De Santis, M | 1 |
| Robert-Gnansia, E | 1 |
| Valti, E | 1 |
| Malm, H | 1 |
| Ornoy, A | 1 |
| Fiedorek, S | 1 |
| Stolle, J | 1 |
| Lee, C | 1 |
| Kosel, BW | 1 |
| Storey, SS | 1 |
| Collier, AC | 1 |
| Oh, DS | 1 |
| Ohning, GV | 1 |
| Pisegna, JR | 1 |
| Hashimoto, T | 1 |
| Mihara, T | 1 |
| Fujishiro, H | 1 |
| Ishihara, S | 1 |
| Amano, Y | 1 |
| Hattori, S | 1 |
| Baldi, F | 3 |
| Nakamura, A | 1 |
| Park, W | 1 |
| Hicks, DM | 1 |
| Khandwala, F | 1 |
| Richter, JE | 3 |
| Abelson, TI | 1 |
| Milstein, C | 1 |
| Rammer, M | 1 |
| Kirchgatterer, A | 1 |
| Höbling, W | 1 |
| Knoflach, P | 1 |
| Stacy, T | 1 |
| Ryan, M | 1 |
| Wootton, T | 1 |
| Willis, J | 1 |
| Hornbuckle, K | 1 |
| Brooks, W | 1 |
| Doviak, M | 1 |
| Isaev, VA | 1 |
| Yüksel, H | 1 |
| Yilmaz, O | 1 |
| Kirmaz, C | 1 |
| Aydoğdu, S | 1 |
| Kasirga, E | 1 |
| Mine, S | 3 |
| Tabata, T | 3 |
| Kishikawa, H | 1 |
| Tanaka, Y | 3 |
| Mantani, N | 1 |
| Ito, K | 1 |
| Kogure, T | 1 |
| Hoshino, A | 1 |
| Kawada, E | 1 |
| Sakamoto, H | 1 |
| Fujita, K | 1 |
| Tamura, J | 1 |
| Littner, MR | 1 |
| Leung, FW | 1 |
| Samra, NK | 1 |
| Genestin, E | 1 |
| Ulualp, S | 1 |
| Brodsky, L | 1 |
| Croom, KF | 1 |
| Remák, E | 1 |
| Brown, RE | 1 |
| Yuen, C | 1 |
| Robinson, A | 1 |
| Manno, M | 1 |
| Hansen, RA | 1 |
| Shaheen, NJ | 1 |
| Schommer, JC | 1 |
| Celikel, CA | 1 |
| Ozdogan, O | 1 |
| Tözün, N | 1 |
| Ulusoy, NB | 1 |
| Kalayci, C | 1 |
| Cappiello, R | 1 |
| Cavoli, C | 1 |
| Ghersi, S | 1 |
| Torresan, F | 1 |
| Roda, E | 1 |
| Wong, CH | 3 |
| Chua, CJ | 1 |
| Liam, CK | 1 |
| Goh, KL | 3 |
| Gunaratnam, NT | 1 |
| Jessup, TP | 1 |
| Lascewski, DP | 1 |
| Devault, KR | 1 |
| Johanson, JF | 1 |
| Liu, S | 1 |
| Sostek, MB | 1 |
| Gupta, SK | 1 |
| Amer, F | 2 |
| Heyman, MB | 2 |
| Castro Fernández, M | 1 |
| García Díaz, E | 1 |
| Larraona, JL | 1 |
| Rodríguez Hornillo, MC | 1 |
| Lamas Rojas, E | 1 |
| Núñez Hospital, D | 1 |
| Pallarés Querol, M | 1 |
| Shimizu, Y | 2 |
| Dobashi, K | 2 |
| Kobayashi, S | 1 |
| Ohki, I | 1 |
| Tokushima, M | 1 |
| Kusano, M | 2 |
| Kawamura, O | 2 |
| Shimoyama, Y | 2 |
| Utsugi, M | 2 |
| Sunaga, N | 1 |
| Ishizuka, T | 2 |
| Mori, M | 3 |
| Demirkan, K | 1 |
| Bozkurt, B | 1 |
| Karakaya, G | 1 |
| Kalyoncu, AF | 1 |
| Sato, A | 1 |
| Tanifuji, Y | 1 |
| Kobayashi, H | 1 |
| Inoue, H | 1 |
| Brørs, O | 1 |
| Mehta, S | 1 |
| Bennett, J | 1 |
| Mahon, D | 1 |
| Rhodes, M | 1 |
| Guimarães, EV | 1 |
| Marguet, C | 1 |
| Camargos, PA | 1 |
| Miura, M | 1 |
| Satoh, S | 1 |
| Tada, H | 1 |
| Saito, M | 1 |
| Inoue, K | 1 |
| Sagae, Y | 1 |
| Kanno, S | 1 |
| Ishikawa, M | 1 |
| Habuchi, T | 1 |
| Winter, HS | 1 |
| Checani, GC | 1 |
| Hogan, DL | 1 |
| Pratha, VS | 1 |
| Qua, CS | 1 |
| Gopala, K | 1 |
| Suzuki, H | 1 |
| Abe, S | 1 |
| Kerr, W | 1 |
| El-Serag, HB | 2 |
| Coté, GA | 1 |
| Ferreira, MR | 1 |
| Rozenberg-Ben-Dror, K | 1 |
| Lundin, C | 1 |
| Nauclér, E | 1 |
| Cibor, D | 1 |
| Ciećko-Michalska, I | 1 |
| Owczarek, D | 1 |
| Szczepanek, M | 1 |
| Maeda, M | 1 |
| Kuribayashi, S | 1 |
| Nagoshi, A | 1 |
| Zai, H | 1 |
| Moki, F | 1 |
| Horikoshi, T | 1 |
| Toki, M | 1 |
| Sugimoto, S | 1 |
| Zhao, JJ | 1 |
| Kawata, T | 1 |
| Ono, A | 1 |
| Yanagitani, N | 1 |
| Kaira, K | 1 |
| Hisada, T | 1 |
| Lu, M | 1 |
| Malladi, V | 1 |
| Agha, A | 1 |
| Abudayyeh, S | 1 |
| Siepman, N | 1 |
| Graham, DY | 1 |
| García de Hombre, AM | 1 |
| Miyoshi, R | 1 |
| Yasunaga, Y | 1 |
| Kizu, T | 1 |
| Inoue, T | 1 |
| Watanabe, C | 1 |
| Matsumoto, Y | 1 |
| Katata, T | 1 |
| Inui, Y | 1 |
| Kohro, T | 1 |
| Nishikawa, M | 1 |
| Fukui, Y | 1 |
| Maruno, T | 1 |
| Hisatsune, H | 1 |
| Xu, JY | 1 |
| Xie, XP | 1 |
| Song, GQ | 1 |
| Hou, XH | 1 |
| Okada, Y | 1 |
| de Argila, CM | 1 |
| Ponce, J | 2 |
| Márquez, E | 1 |
| Galván, J | 2 |
| Porcel, J | 2 |
| Barron, JJ | 1 |
| Tan, H | 1 |
| Spalding, J | 1 |
| Bakst, AW | 1 |
| Singer, J | 1 |
| García Rodríguez, LA | 1 |
| Ruigómez, A | 1 |
| Panés, J | 1 |
| Reynolds, EW | 1 |
| Kinnard, TB | 1 |
| Kriss, VM | 1 |
| Perman, JA | 1 |
| Márquez-Contreras, E | 1 |
| Gil, V | 1 |
| López, J | 1 |
| Pérez-Manauta, J | 1 |
| Kouklakis, G | 1 |
| Moschos, J | 1 |
| Paikos, D | 1 |
| Tagarakis, G | 1 |
| Rouska, E | 1 |
| Mpoumponaris, A | 1 |
| Lyrantzopoulos, N | 1 |
| Molyvas, E | 1 |
| Minopoulos, G | 1 |
| Khoshoo, V | 1 |
| Dhume, P | 1 |
| Duygu, H | 1 |
| Ozerkan, F | 1 |
| Saygi, S | 1 |
| Akyüz, S | 1 |
| Calabrese, C | 1 |
| Liguori, G | 1 |
| Gabusi, V | 1 |
| Gionchetti, P | 1 |
| Rizzello, F | 1 |
| Straforini, G | 1 |
| Brugnera, R | 1 |
| Di Febo, G | 1 |
| Mouly, S | 1 |
| Charlemagne, A | 1 |
| Le Jeunne, P | 1 |
| Fagnani, F | 1 |
| Nos, P | 1 |
| Florent, C | 1 |
| Dobrilla, G | 2 |
| Di Fede, F | 1 |
| Cadiot, G | 1 |
| Vissuzaine, C | 1 |
| Pospai, D | 1 |
| Ruszniewski, P | 1 |
| Potet, F | 1 |
| Mignon, M | 1 |
| Mee, AS | 1 |
| Rowley, JL | 1 |
| Berstad, A | 2 |
| Sampliner, RE | 2 |
| Camargo, E | 1 |
| Viljakka, M | 1 |
| Nevalainen, J | 1 |
| Isolauri, J | 1 |
| Leufkens, H | 1 |
| Claessens, A | 1 |
| Heerdink, E | 1 |
| van Eijk, J | 1 |
| Lamers, CB | 1 |
| Castell, DO | 7 |
| Chiocca, JC | 1 |
| Salis, GB | 1 |
| Stolte, M | 3 |
| Meining, A | 2 |
| Schmitz, JM | 2 |
| Alexandridis, T | 3 |
| Seifert, E | 3 |
| Ouatu-Lascar, R | 1 |
| Triadafilopoulos, G | 2 |
| Peghini, PL | 1 |
| Bracy, NA | 1 |
| Hetzel, D | 1 |
| Blum, RA | 1 |
| Kidd, SL | 1 |
| Shi, H | 1 |
| Jennings, DE | 1 |
| Greski-Rose, PA | 1 |
| Jaspersen, D | 1 |
| Diehl, KL | 1 |
| Schoeppner, H | 1 |
| Geyer, P | 1 |
| Martens, E | 1 |
| Newton, M | 1 |
| Burnham, WR | 1 |
| Kamm, MA | 1 |
| Anderson, C | 1 |
| Khoury, R | 1 |
| Janczewska, I | 1 |
| Sagar, M | 1 |
| Sjöstedt, S | 1 |
| Hammarlund, B | 1 |
| Iwarzon, M | 1 |
| Seensalu, R | 1 |
| Kromer, W | 1 |
| Horbach, S | 1 |
| Lühmann, R | 1 |
| Colwell, HH | 2 |
| Mathias, SD | 2 |
| Pasta, DJ | 2 |
| Henning, JM | 3 |
| Condra, LJ | 1 |
| Morreale, AP | 1 |
| Stolley, SN | 1 |
| Marcus, D | 1 |
| Feldman, M | 1 |
| Cryer, B | 1 |
| Sammer, D | 1 |
| Lee, E | 1 |
| Spechler, SJ | 1 |
| Fujisaki, T | 1 |
| Matsuoka, H | 1 |
| Yamada, S | 1 |
| Morimoto, I | 1 |
| Eto, S | 1 |
| Aibe, T | 1 |
| McCaffrey, E | 1 |
| Gerson, LB | 1 |
| Hatton, BN | 1 |
| Ryono, R | 1 |
| Jones, W | 1 |
| Pulliam, G | 3 |
| Capurso, L | 1 |
| Campbell, DR | 1 |
| Fludas, C | 1 |
| Galmiche, JP | 1 |
| Nelson, WW | 1 |
| Vermeulen, LC | 1 |
| Geurkink, EA | 1 |
| Ehlert, DA | 1 |
| Reichelderfer, M | 1 |
| Thomson, AB | 1 |
| Aviv, JE | 1 |
| Liu, H | 1 |
| Parides, M | 1 |
| Kaplan, ST | 1 |
| Close, LG | 1 |
| Murthy, U | 1 |
| Hayden, CW | 1 |
| Malagon, IB | 1 |
| Wendel, C | 1 |
| Kovacs, TO | 1 |
| Franco, MT | 1 |
| Salvia, G | 1 |
| Terrin, G | 1 |
| Spadaro, R | 1 |
| De Rosa, I | 1 |
| Iula, VD | 1 |
| Cucchiara, S | 1 |
| Vieth, M | 1 |
| Mukherjee, S | 1 |
| Lee, P | 1 |
| Buchner, A | 1 |
| Gavin, M | 1 |
| McCarthy, DM | 1 |
| Xue, S | 1 |
| Bardou, M | 1 |
| Schwizer, W | 1 |
| Thumshirn, M | 1 |
| Dent, J | 1 |
| Guldenschuh, I | 1 |
| Menne, D | 1 |
| Cathomas, G | 1 |
| Belafsky, PC | 1 |
| Postma, GN | 1 |
| Koufman, JA | 1 |
| McGuigan, JE | 1 |
| Lukasik, N | 1 |
| Tytgat, GN | 2 |
| Raisch, DW | 1 |
| Klaurens, LM | 1 |
| Hayden, C | 1 |
| Malagon, I | 1 |
| Jacobsen, CD | 1 |
| Hansen, T | 1 |
| Farup, PG | 1 |
| Juul-Hansen, PH | 1 |
| Caro, JJ | 1 |
| Salas, M | 1 |
| Ward, A | 1 |
| Michaud, L | 1 |
| Shaghaghi, EK | 1 |
| Popon, M | 1 |
| Laurence, M | 1 |
| Mougenot, JF | 1 |
| Hankard, R | 1 |
| Navarro, J | 1 |
| Jacoz-Aigrain, E | 1 |
| Morreale, A | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Geboes, K | 1 |
| Dekker, W | 1 |
| Mulder, CJ | 1 |
| Nusteling, K | 1 |
| Saigusa, H | 1 |
| Niimi, S | 1 |
| Saigusa, U | 1 |
| Yagi, T | 1 |
| Miller, DP | 1 |
| Ofman, JJ | 1 |
| Xiao, F | 1 |
| Maceri, DR | 1 |
| Zim, S | 1 |
| Macaigne, G | 1 |
| Boivin, JF | 1 |
| Simon, P | 1 |
| Chayette, C | 1 |
| Cheaib, S | 1 |
| Deplus, R | 1 |
| Beck, IT | 1 |
| Kazantsev, GB | 1 |
| Schwesinger, WH | 1 |
| Heim-Hall, J | 1 |
| Hinder, RA | 1 |
| Lanzani, A | 1 |
| Melotti, G | 1 |
| Bown, RL | 1 |
| Kim, JD | 1 |
| Laine, L | 1 |
| Dhir, V | 1 |
| de Silva, KK | 1 |
| Young, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing Dexlansoprazole With Double-dose Lansoprazole to Achieve Sustained Symptomatic Response in Overweight and Obesity Patients With Reflux Esophagitis in Los Angeles Grades A & B[NCT02759393] | Phase 4 | 200 participants (Anticipated) | Interventional | 2015-10-31 | Enrolling by invitation | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once-daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251719] | Phase 3 | 2,054 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (30 mg QD and 60 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Nonerosive Gastroesophageal Reflux Disease (GERD)[NCT00321984] | Phase 3 | 947 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg Once- Daily [QD] and 90 mg QD) and an Active Comparator, Lansoprazole (30 mg QD) on Healing of Erosive Esophagitis[NCT00251693] | Phase 3 | 2,038 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Phase III: The Study of Acid Reflux in Children With Asthma[NCT00442013] | Phase 4 | 306 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multi-center Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Neonates With Clinically-Evident Gastroesophageal Reflux Disease.[NCT00174928] | Phase 1 | 24 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| A Phase 1, Single- and Repeated-Dose, Randomized, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Lansoprazole in Infants With Clinically-Evident Gastroesophageal Reflux Disease.[NCT00220818] | Phase 1 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Effectiveness of Vonoprazan vs Omeprazole as Empiric Therapy for Gastroesophageal Reflux Disease (GERD) Patients Without Alarm Features in a Primary Care Setting: A Pragmatic, Randomized, Single Blind Study[NCT04028466] | Phase 4 | 82 participants (Actual) | Interventional | 2019-05-26 | Terminated (stopped due to Budget for the study was withdrawn and discontinued) | ||
| A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux[NCT00324974] | Phase 3 | 162 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase 3 Study to Evaluate the Efficacy and Safety of Dexlansoprazole MR (60 mg Once-Daily (QD) and 90 mg QD) Compared to Placebo on Symptom Relief in Subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease (GERD)[NCT00251745] | Phase 3 | 908 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Phase 3, Open-Label Study to Assess the Long-Term Safety of Dexlansoprazole MR (60 mg QD and 90 mg QD)[NCT00255190] | Phase 3 | 591 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of Dexlansoprazole MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis[NCT00255164] | Phase 3 | 451 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects With Healed Erosive Esophagitis.[NCT00321737] | Phase 3 | 445 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| A Multicenter, Randomized, Double-blinded, Placebo-controlled Pilot Study to Evaluate the Efficacy and Safety of Rebamipide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis (REPAIR)[NCT02755753] | Phase 4 | 143 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD[NCT00410592] | Phase 4 | 90 participants (Anticipated) | Interventional | 2006-10-31 | Completed | ||
| An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan[NCT03079050] | Phase 4 | 33 participants (Actual) | Interventional | 2017-02-27 | Completed | ||
| A Phase 3 Multicenter, Randomized, Double-Blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy of TAK-390MR (30 mg QD) Compared to Placebo on Relief of Nocturnal Heartburn in Subjects With Symptomatic Gastroesophageal Reflux Disease (G[NCT00627016] | Phase 3 | 305 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Phase 1, Randomized, Open-Label, Parallel Group, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Dexlansoprazole Modified Release Capsules (30 mg and 60 mg) in Adolescents With Symptomatic Gastroesophageal Reflux Disease[NCT00847210] | Phase 1 | 36 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy[NCT00847808] | Phase 3 | 178 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Economic Impact of Guidelines for Gastroesophageal Reflux Disease[NCT00057174] | 484 participants (Anticipated) | Interventional | Completed | ||||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| Clinical Application of Vagus Nerve Preservation in Minimally Invasive Surgery for Early Lung Cancer[NCT04125979] | 120 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | |||
| Prospective Randomized Controlled Study on the Effects of Vagus Nerve Pulmonary Branch Preservation During Video-assisted Thoracic Surgery Lobectomy in Non-small Cell Lung Cancer: Can it Decrease Postoperative Cough and Pulmonary Complications[NCT04923412] | 214 participants (Anticipated) | Interventional | 2021-07-01 | Recruiting | |||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Pharmacogenomics-Based Tailor-Made Strategy for Eradication of Helicobacter Pylori[NCT00149084] | Phase 3 | 296 participants | Interventional | 2003-04-30 | Recruiting | ||
| Effect of the CYP2C19 Polymorphism in Helicobacter Pylori Eradication[NCT03650543] | Phase 4 | 133 participants (Actual) | Interventional | 2012-09-10 | Completed | ||
| A Randomized, Double-blind, Placebo-controlled Study of Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy[NCT01328652] | Phase 4 | 80 participants (Anticipated) | Interventional | 2011-06-30 | Not yet recruiting | ||
| Comparison of the Ease of Swallowability of B/F/TAF Placebo Compared to DTG/ABC/3TC Placebo[NCT04600687] | 50 participants (Actual) | Interventional | 2018-11-06 | Completed | |||
| Barrett's Esophagus Study (BEST) Trial - a Multi-Center and Endoscopic Outcomes Project[NCT00586404] | 1,250 participants (Actual) | Observational | 2007-11-30 | Terminated (stopped due to lack of enrollment) | |||
| Pharmacodynamic Dose-Response of S-Tenatoprazole-Na (STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers[NCT00284908] | Phase 1 | 32 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.[NCT00282555] | Phase 2 | 450 participants | Interventional | 2006-02-28 | Suspended | ||
| Assessing the Impacts of an Upper Esophageal Sphincter Assist Device on Laryngeal Symptoms and Salivary Pepsin: A Pilot Study[NCT02552966] | 20 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Post-nasal Drainage as an Extraesophageal Manifestation of Reflux[NCT00199953] | Phase 2 | 50 participants | Interventional | 2002-06-30 | Completed | ||
| A Randomized, Placebo-Controlled Assessment of Lansoprazole 30 mg Bid in the Treatment of Gastroesophageal Reflux Associated With Laryngitis[NCT00369265] | Phase 4 | 18 participants (Actual) | Interventional | 2006-08-31 | Terminated (stopped due to Pharmaceutical company purchased by another company and funding was terminated.) | ||
| A Prospective Evaluation of the Utility, Optimal Cutoff and Positive Predictive Value of a Pharyngeal pH Probe for Predicting Proton Pump Inhibitor Response in Treatment Naive Laryngopharyngeal Reflux[NCT01755221] | 80 participants (Anticipated) | Interventional | 2012-08-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: Week 8
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 77.8 |
| Dexlansoprazole MR 90 mg QD | 86.3 |
| Lansoprazole 30 mg QD | 78.9 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades C or D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 87.6 |
| Dexlansoprazole MR 90 mg QD | 93.3 |
| Lansoprazole 30 mg QD | 87.7 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 69.7 |
| Dexlansoprazole MR 90 mg QD | 70.6 |
| Lansoprazole 30 mg QD | 65.4 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 4 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 80.1 |
| Dexlansoprazole MR 90 mg QD | 80.4 |
| Lansoprazole 30 mg QD | 77.0 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 86.9 |
| Dexlansoprazole MR 90 mg QD | 89.4 |
| Lansoprazole 30 mg QD | 84.6 |
Percentage of subjects with complete healing of EE as assessed by endoscopy. Change in LA Esophagitis Classification grades A, B, C, D to healed was measured. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251719)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 93.1 |
| Dexlansoprazole MR 90 mg QD | 94.9 |
| Lansoprazole 30 mg QD | 91.5 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Placebo QD | 25.0 |
| Dexlansoprazole MR 30 mg QD | 50.3 |
| Dexlansoprazole MR 60 mg QD | 49.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Median) |
|---|---|
| Placebo QD | 18.5 |
| Dexlansoprazole MR 30 mg QD | 54.9 |
| Dexlansoprazole MR 60 mg QD | 50.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Placebo QD | 47.1 |
| Dexlansoprazole MR 30 mg QD | 67.6 |
| Dexlansoprazole MR 60 mg QD | 65.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321984)
Timeframe: 4 weeks
| Intervention | percentage of days (Median) |
|---|---|
| Placebo QD | 51.7 |
| Dexlansoprazole MR 30 mg QD | 80.8 |
| Dexlansoprazole MR 60 mg QD | 76.9 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of erosive esophagitis as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 74.1 |
| Lansoprazole 30 mg QD | 65.0 |
Percentage of subjects with baseline EE grade C or D combined who have complete healing of EE as assessed by endoscopy for Change in LA Esophagitis Classification Grades C and D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 88.9 |
| Dexlansoprazole MR 90 mg QD | 83.8 |
| Lansoprazole 30 mg QD | 74.5 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A (greater than or equal to 1 mucosal break and less than 5 mm). If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 85.3 |
| Dexlansoprazole MR 90 mg QD | 85.8 |
| Lansoprazole 30 mg QD | 79.0 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 66.2 |
| Dexlansoprazole MR 90 mg QD | 68.8 |
| Lansoprazole 30 mg QD | 64.8 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 4 Weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 77.0 |
| Dexlansoprazole MR 90 mg QD | 78.8 |
| Lansoprazole 30 mg QD | 76.5 |
Percentage of subjects with complete healing of EE as assessed by endoscopy was analyzed for change in LA Esophagitis Classification grades A, B, C, or D to healed. Healed is defined as anything that is less than the criterion for Grade A. If it doesn't meet the A criterion, it's counted as healed. (NCT00251693)
Timeframe: 8 weeks
| Intervention | Percentage of subjects (Number) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 92.3 |
| Dexlansoprazole MR 90 mg QD | 92.2 |
| Lansoprazole 30 mg QD | 86.1 |
Presence and degree of airway hyperresponsiveness; change from baseline to 24 weeks for airways reactivity assessed by methacholine post-diluent baseline (PC20) after medication holds (NCT00442013)
Timeframe: Measured at Weeks 0 and 24
| Intervention | mg/mL (Mean) |
|---|---|
| Lansoprazole Group | 2.6 |
| Placebo Group | 2.5 |
ASUI is a utility score that ranges from 0 to 1, with higher values indicating better asthma control; info obtained from questionnaire about asthma symptoms; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 0.86 |
| Placebo Group | 0.88 |
Scores range from 1 to 7 with higher values indicating better asthma-related quality of life; questionnaire measures functional impairments that are most troublesome to children as a result of their asthma; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 5.8 |
| Placebo Group | 6.0 |
Score ranges from 0 to 6, a lower score indicated better asthma control. Scores above 1.5 are indicative of poor asthma control; score obtained from questionnaire with 6 questions related to asthma control and FEV (amount of air expired in the first second during a forced expiratory maneuver); number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 24
| Intervention | score (Mean) |
|---|---|
| Lansoprazole Group | 1.1 |
| Placebo Group | 1.0 |
A measure of pulmonary function, specifically the amount of expired air in the first second during a forced expiratory maneuver while seated; test performed at least 4 hours after last dose of short-acting bronchodilator and at least 12 hours after long-acting bronchodilator; number presents an average of the change from baseline to all follow-up points (NCT00442013)
Timeframe: Measured at Weeks 0, 4, 8, 12, 16, 20, 24
| Intervention | Liters (Mean) |
|---|---|
| Lansoprazole Group | 2.2 |
| Placebo Group | 2.3 |
"Episodes of poor asthma control are defined as any one of the following:~2 consecutive days with peak flow at less than 70% of baseline~prescription of oral corticosteroids for asthma~seeking urgent medical care for asthma symptoms~EPAC was measured by review of daily diaries that were maintained over the entire course of followup, i.e, 24 weeks" (NCT00442013)
Timeframe: Measured daily for 24 weeks by diary
| Intervention | number of episodes of poor asthma contrl (Number) |
|---|---|
| Lansoprazole Group | 230 |
| Placebo Group | 184 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00251745)
Timeframe: 4 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Placebo QD | 24.9 |
| Dexlansoprazole MR 60 mg QD | 44.8 |
| Dexlansoprazole MR 90 mg QD | 49.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00251745)
Timeframe: 4 weeks
| Intervention | percentage of days (Median) |
|---|---|
| Placebo QD | 17.0 |
| Dexlansoprazole MR 60 mg QD | 45.7 |
| Dexlansoprazole MR 90 mg QD | 52.7 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00251745)
Timeframe: 4 weeks
| Intervention | percentage of days (Mean) |
|---|---|
| Placebo QD | 49.6 |
| Dexlansoprazole MR 60 mg QD | 62.0 |
| Dexlansoprazole MR 90 mg QD | 64.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00251745)
Timeframe: 4 weeks
| Intervention | percentage of days (Median) |
|---|---|
| Placebo QD | 51.0 |
| Dexlansoprazole MR 60 mg QD | 72.3 |
| Dexlansoprazole MR 90 mg QD | 76.6 |
Mean overall composite Quality of Life (QOL) score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL. (NCT00255190)
Timeframe: Baseline and Month 1
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.54 |
| Dexlansoprazole MR 90 mg QD | 0.54 |
Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity). (NCT00255190)
Timeframe: Baseline and Month 1
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.95 |
| Dexlansoprazole MR 90 mg QD | -0.85 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | U/L (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 1.6 |
| Dexlansoprazole MR 90 mg QD | 0.5 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | U/L (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.4 |
| Dexlansoprazole MR 90 mg QD | -0.4 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | U/L (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.9 |
| Dexlansoprazole MR 90 mg QD | 0.6 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mg/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.1 |
| Dexlansoprazole MR 90 mg QD | 0.0 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mg/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.25 |
| Dexlansoprazole MR 90 mg QD | -0.04 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mg/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.04 |
| Dexlansoprazole MR 90 mg QD | -0.04 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mm Hg (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 4.0 |
| Dexlansoprazole MR 90 mg QD | 0.6 |
Hematocrit measurement percent is the absolute difference in Hematocrit values, and not percentage difference. (NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | percentage (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -1.98 |
| Dexlansoprazole MR 90 mg QD | -0.93 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | g/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.29 |
| Dexlansoprazole MR 90 mg QD | -0.05 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mg/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.09 |
| Dexlansoprazole MR 90 mg QD | 0.06 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | g/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.67 |
| Dexlansoprazole MR 90 mg QD | 0.56 |
Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL. (NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.56 |
| Dexlansoprazole MR 90 mg QD | 0.61 |
Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity). (NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -1.08 |
| Dexlansoprazole MR 90 mg QD | -0.95 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | Platelet Count x10 to the 3/mcL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -12.7 |
| Dexlansoprazole MR 90 mg QD | -1.9 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | beats per minute (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.5 |
| Dexlansoprazole MR 90 mg QD | -1.3 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | Red Blood Cell count x10 to the 6/μL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.31 |
| Dexlansoprazole MR 90 mg QD | -0.11 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | pg/mL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 155.8 |
| Dexlansoprazole MR 90 mg QD | 115.4 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mm Hg (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 3.8 |
| Dexlansoprazole MR 90 mg QD | 1.9 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | mg/dL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.02 |
| Dexlansoprazole MR 90 mg QD | -0.01 |
(NCT00255190)
Timeframe: Baseline and Month 12
| Intervention | White Blood Cell count x10 to the 3/mcL (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -0.20 |
| Dexlansoprazole MR 90 mg QD | 0.04 |
Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL. (NCT00255190)
Timeframe: Baseline and Month 3
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.61 |
| Dexlansoprazole MR 90 mg QD | 0.56 |
Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity). (NCT00255190)
Timeframe: Baseline and Month 3
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -1.09 |
| Dexlansoprazole MR 90 mg QD | -0.91 |
Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL. (NCT00255190)
Timeframe: Baseline and Month 6
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.58 |
| Dexlansoprazole MR 90 mg QD | 0.56 |
Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity). (NCT00255190)
Timeframe: Baseline and Month 6
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -1.05 |
| Dexlansoprazole MR 90 mg QD | -0.93 |
Mean overall composite QOL score changes were computed in response to 30 questions, each scored 0 (lowest QOL) to 5 (highest QOL). Positive changes from baseline indicate improved QOL. (NCT00255190)
Timeframe: Baseline and Month 9
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | 0.64 |
| Dexlansoprazole MR 90 mg QD | 0.60 |
Mean overall composite symptom-severity score changes were computed in response to 20 questions, each scored 0 (no symptoms) to 5 (most severe symptoms). Negative changes from baseline indicate improvement in symptoms (decrease in severity). (NCT00255190)
Timeframe: Baseline and Month 9
| Intervention | score on a scale (Mean) |
|---|---|
| Dexlansoprazole MR 60 mg QD | -1.17 |
| Dexlansoprazole MR 90 mg QD | -0.89 |
Normal=normal tissue; Unknown Baseline = Baseline biopsy not available; Abnormal diagnoses include: Reactive Gastropathy, Chronic Gastritis, Intestinal Metaplasia, Reflective Observation Mucosa-Associated Lymphoid Tissue Lymphoma, Other Abnormal. (NCT00255190)
Timeframe: Baseline and Final Visit (up to 12 months)
| Intervention | subjects (Number) | |||||
|---|---|---|---|---|---|---|
| Normal Baseline to Normal Final Visit | Normal Baseline to Abnormal Final Visit | Abnormal Baseline to Normal Final Visit | Abnormal Baseline to Abnormal Final Visit | Unknown Baseline to Normal Final Visit | Unknown Baseline to Abnormal Final Visit | |
| Dexlansoprazole MR 60 mg QD | 39 | 11 | 21 | 29 | 1 | 1 |
| Dexlansoprazole MR 90 mg QD | 114 | 61 | 47 | 60 | 11 | 4 |
Normal=normal tissue; Unknown Baseline = Baseline biopsy not available; Abnormal diagnoses include: Reactive Gastropathy, Chronic Gastritis, Intestinal Metaplasia, Reflective Observation Mucosa-Associated Lymphoid Tissue Lymphoma, Other Abnormal. (NCT00255190)
Timeframe: Baseline and Final Visit (up to 12 months)
| Intervention | subjects (Number) | |||||
|---|---|---|---|---|---|---|
| Normal Baseline to Normal Final Visit | Normal Baseline to Abnormal Final Visit | Abnormal Baseline to Normal Final Visit | Abnormal Baseline to Abnormal Final Visit | Unknown Baseline to Normal Final Visit | Unknown Baseline to Abnormal Final Visit | |
| Dexlansoprazole MR 60 mg QD | 55 | 8 | 17 | 21 | 2 | 0 |
| Dexlansoprazole MR 90 mg QD | 198 | 35 | 33 | 35 | 2 | 3 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 29.5 |
| Dexlansoprazole MR 60 mg QD | 79.7 |
| Dexlansoprazole MR 90 mg QD | 79.2 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 19.2 |
| Dexlansoprazole MR 60 mg QD | 95.8 |
| Dexlansoprazole MR 90 mg QD | 94.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 48.3 |
| Dexlansoprazole MR 60 mg QD | 87.1 |
| Dexlansoprazole MR 90 mg QD | 85.4 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 50.0 |
| Dexlansoprazole MR 60 mg QD | 98.3 |
| Dexlansoprazole MR 90 mg QD | 97.1 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
| Dexlansoprazole MR 90 mg QD | 64.5 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00255164)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 25.7 |
| Dexlansoprazole MR 60 mg QD | 86.6 |
| Dexlansoprazole MR 90 mg QD | 82.1 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 36.0 |
| Dexlansoprazole MR 30 mg QD | 83.3 |
| Dexlansoprazole MR 60 mg QD | 78.4 |
The percentage was calculated as the days that were heartburn-free out of the total number of days for which either a daytime or nighttime result was reported. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 28.6 |
| Dexlansoprazole MR 30 mg QD | 96.1 |
| Dexlansoprazole MR 60 mg QD | 90.9 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Mean) |
|---|---|
| Placebo QD | 57.7 |
| Dexlansoprazole MR 30 mg QD | 89.3 |
| Dexlansoprazole MR 60 mg QD | 86.0 |
The percentage was calculated as the nights that were heartburn-free out of the total number of days for which a nighttime result was marked. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Days (Median) |
|---|---|
| Placebo QD | 71.7 |
| Dexlansoprazole MR 30 mg QD | 98.9 |
| Dexlansoprazole MR 60 mg QD | 96.2 |
Crude rates analyzed maintenance of healed EE from baseline of this study and considered prematurely discontinued subjects as relapsed. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 14.3 |
| Dexlansoprazole MR 30 mg QD | 66.4 |
| Dexlansoprazole MR 60 mg QD | 66.4 |
Percentage of subjects who maintained complete healing of erosive esophagitis as assessed by endoscopy. In the life table method, subjects without post-baseline endoscopy were included as censored; subjects who did not have a recurrence of EE and did not complete the study were also considered censored. (NCT00321737)
Timeframe: 6 months
| Intervention | Percentage of Subjects (Number) |
|---|---|
| Placebo QD | 27.2 |
| Dexlansoprazole MR 30 mg QD | 74.9 |
| Dexlansoprazole MR 60 mg QD | 82.5 |
Percentage calculated by the number of heartburn-free nights out of the total number of nights during the treatment period with a diary entry indicating presence or absence of nighttime heartburn in subjects who had ≥1 diary entry indicating presence or absence of nighttime heartburn, as indicated by the subject's daily diary. Subjects indicate the presence (Yes/No) of nocturnal heartburn symptoms in a Daily Electronic Diary. Nights missing diary results were excluded from the numerator and denominator. (NCT00627016)
Timeframe: 4 Weeks
| Intervention | Percentage of nights (Median) |
|---|---|
| Placebo | 35.7 |
| Dexlansoprazole 30 mg QD | 73.1 |
Relief of nighttime heartburn was defined as 6 of 7 nights with no heartburn and at most 1 night with mild heartburn; lack of relief of nighttime heartburn was defined as 2 or more out of 7 nights with heartburn, or 1 night with at least moderate heartburn. Subjects indicate the presence and severity (mild, moderate, severe, or very severe) of nocturnal heartburn in a Daily Electronic Diary. The percentage was calculated as the number of subjects with relief of nighttime heartburn divided by the number of subjects whose relief status could be determined. (NCT00627016)
Timeframe: Last 7 days of treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 19.6 |
| Dexlansoprazole 30 mg QD | 47.5 |
Relief of GERD-associated sleep disturbance was defined as 6 of 7 nights with no GERD associated sleep disturbances; lack of relief of GERD-associated sleep disturbance was defined as 2 or more out of 7 nights with GERD-associated sleep disturbance. Subjects indicate the presence (Yes/No) of GERD associated sleep disturbance in a Daily Electronic Diary. The percentage was calculated as the number of subjects with relief of GERD-associated sleep disturbance divided by the number of subjects whose relief status could be determined. (NCT00627016)
Timeframe: Last 7 days of treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Placebo | 47.9 |
| Dexlansoprazole 30 mg QD | 69.7 |
Vz/F is the distribution of a drug between plasma and the rest of the body following oral administration, calculated as CL/F divided by λz. (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | L (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 28.90 |
| Dexlansoprazole MR 60 mg QD | 58.50 |
AUC(0-24) is measure of Area Under the Curve over the dosing interval (tau) (AUC(0-tau]), where tau is the length of the dosing interval - 24 hours in this study). (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | ng*hr/mL/mg (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 2886.26 |
| Dexlansoprazole MR 60 mg QD | 5119.81 |
Area Under the Plasma Concentration Versus Time Curve (AUC(0-tlqc)) is a measure of total plasma exposure to the drug from Time 0 to Time of the Last Quantifiable Concentration (AUC[0-tlqc]). (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | ng*hr/mL/mg (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 2842.32 |
| Dexlansoprazole MR 60 mg QD | 5113.72 |
Maximum Observed Plasma Concentration (Cmax) is the peak plasma concentration of a drug after administration, obtained directly from the plasma concentration-time curve. (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | ng/mL (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 691 |
| Dexlansoprazole MR 60 mg QD | 1136 |
CL/F is apparent clearance of the drug from the plasma, calculated as the drug dose divided AUC(0-24), expressed in L/hr. (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | liter/hr (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 12.81 |
| Dexlansoprazole MR 60 mg QD | 15.29 |
Terminal elimination rate constant (λz) is the rate at which drugs are eliminated from the body. (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | 1/hr (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 0.5264 |
| Dexlansoprazole MR 60 mg QD | 0.3404 |
Terminal Phase Elimination Half-life (T1/2) is the time required for half of the drug to be eliminated from the plasma. (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | hours (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 1.66 |
| Dexlansoprazole MR 60 mg QD | 2.59 |
Tmax: Time to reach the Maximum Plasma Concentration (Cmax), equal to time (hours) to Cmax, as observed on Day 7. (NCT00847210)
Timeframe: After 7 days of dosing.
| Intervention | hours (Mean) |
|---|---|
| Dexlansoprazole MR 30 mg QD | 4.65 |
| Dexlansoprazole MR 60 mg QD | 3.31 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.20 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.10 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.14 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.03 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.00 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.09 |
PAGI-SYM is a 20-item self-reported questionnaire that measures symptom severity of upper gastrointestinal disorders across six subscales (nausea/vomiting, fullness/early satiety, bloating, upper abdominal pain, lower abdominal pain, heartburn/regurgitation) which are summarized by individual subscale scores and a total score. The items are rated on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (very severe). Higher scores indicate higher symptom severity and thus negative changes from baseline indicate decrease in symptom severity. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | -0.08 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.02 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.05 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.27 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.03 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.10 |
PAGI-QOL is a 30-item self-reported instrument assessing health-related quality of life impact of upper gastrointestinal disorders. It includes 30 items across five subscales (daily activities, clothing, diet/food habits, relationship, psychological well-being and distress), scored on a 6-point Likert scale with subscale and total score ranging from 0 (none) to 5 (all the time). For reporting purposes, the scores are reversed and higher scores reflect improved quality of life and positive changes from baseline indicate improved quality of life. (NCT00847808)
Timeframe: Baseline and Week 6.
| Intervention | units on a scale (Mean) |
|---|---|
| Dexlansoprazole MR QD | 0.09 |
Well-controlled participants were defined to be participants who completed the study having at least 23 days of evaluable diary entries between Days 15 and 42, inclusive, and had ≤4 occurrences of heartburn during this period. (NCT00847808)
Timeframe: Week 3 through Week 6
| Intervention | percent of participants (Number) |
|---|---|
| Dexlansoprazole MR QD | 88 |
GERDQ score. Scale of 0-12, higher score indicates increased symptom severity. (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 8.6 |
NGSSI questionnaire score (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 26.8 |
Respiratory symptom index (RSI) score. Values between 0 and 45. Higher value is associated with increased symptom severity. (NCT02552966)
Timeframe: 2 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| UESAD | 19.4 |
Average salivary pepsin concentration (NCT02552966)
Timeframe: 2 weeks
| Intervention | ng/mL (Mean) |
|---|---|
| UESAD | 158.4 |
62 reviews available for lansoprazole and Esophageal Reflux
| Article | Year |
|---|---|
Recent advances in proton pump inhibitors and management of acid-peptic disorders.
Topics: Animals; Anti-Ulcer Agents; Gastric Acid; Gastroesophageal Reflux; Helicobacter Infections; Humans; | 2007 |
Pharmacologic treatment of GERD: Where we are now, and where are we going?
Topics: Cimetidine; Esomeprazole; Esophageal Mucosa; Gastroesophageal Reflux; Humans; Lansoprazole; Omeprazo | 2020 |
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
Topics: Adult; Antifungal Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Cytochrome P-45 | 2016 |
Nocturnal gastroesophageal reflux disease: issues, implications, and management strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Heartburn; Humans; Lansoprazole; O | 2008 |
[Proton pump inhibitors, a family of drugs in continuous expansion].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Inflammatory Agents, Non-Steroidal; Barrett E | 2000 |
Dexlansoprazole MR.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Disease; Anti-Ulcer Agents; Delayed-Action Preparatio | 2009 |
Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexlansoprazole; Drug Interactions; Esophagitis; Gastroesop | 2010 |
[How to choose correct proton pump inhibitors to patients with GERD?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cytochrome P-450 Enzyme System; Drug Interactions; Gastroes | 2010 |
Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansopra | 2010 |
Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Delayed-Action Preparations; Dexlansoprazole; Esop | 2010 |
Dexlansoprazole MR: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Delayed-Action Preparations; Dexlansoprazole; Esophagitis; | 2011 |
Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Child; Child, Preschool; Cross-Ove | 2011 |
Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chest Pain; Esophagus; Gastroesophageal Reflux; Heartburn; | 2011 |
Dexlansoprazole MR for the management of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Delayed-Action Preparations; Dexlansopra | 2011 |
Do proton pump inhibitors protect against cancer progression in GERD?
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Barrett Esop | 2013 |
Gastroesophageal reflux disease: new treatments.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Esomeprazol | 2002 |
Motion--Helicobacter pylori worsens GERD: arguments for the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials a | 2002 |
Motion--Helicobacter pylori causes or worsens GERD: arguments against the motion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
The pharmacology and clinical relevance of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Drug Therapy, | 2002 |
Lansoprazole: in the management of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Ulcer Agents; Child; Child, Pres | 2003 |
Reflux disease and Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Endos | 2003 |
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, | 2003 |
The impact of gastroesophageal reflux disease on quality of life.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Combined Modality Therapy; Cross-Over St | 2003 |
[All proton pump inhibitors are equally efficacious in standard dosages].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
Improving health-related quality of life in gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansopr | 2003 |
[Use of proton pump inhibitors in the treatment of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; | 2003 |
Proton pump inhibitors in children: a review.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Drug Interactions; Esophagitis, P | 2003 |
Managing gastro-oesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Gastroesophageal Reflux; Humans; | 2004 |
[Primary care for GEDR].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Circadian Rhythm; Drug Therapy, Combination | 2004 |
[Evaluation of the efficacy and the cost-effectiveness of maintenance treatment of gastroesophageal reflux disease: proton pump inhibitor versus histamine-2-receptor antagonist].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost-Benefit Analysis; Drug Therapy, Combin | 2004 |
[PPI: new strategies for GERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; Ci | 2004 |
Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Biological Availability; Dose-Response Relatio | 2004 |
Management of acid-related disorders in patients with dysphagia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Age Factors; Aged; Aged, 80 an | 2004 |
Effectiveness of proton pump inhibitors: beyond cost.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Enzyme Inhibitors; Esophagitis; Gastroesoph | 2004 |
Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Esophagitis, Peptic; Famotidine; Gastroesophageal Reflux; H | 2005 |
Lansoprazole oro-dispersible tablet : pharmacokinetics and therapeutic use in acid-related disorders.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Esomeprazole; Gastroesophageal Reflux; H | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Benzimidazoles; | 2005 |
Lansoprazole: in the treatment of gastro-oesophageal reflux disease in children and adolescents.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Gas | 2005 |
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo | 2005 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; | 2006 |
[Dosaging of proton pumps inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; | 2006 |
Treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Adult; Anti-Ulcer Agents; Barre | 2006 |
[Therapeutic innovations in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Catheter Ablation; Cisapride; End | 2007 |
CYP2C19 pharmacogenomics associated with therapy of Helicobacter pylori infection and gastro-esophageal reflux diseases with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Biotransf | 2007 |
[Lansoprazol].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Controlled Clinical Trials as Topic; Duo | 1995 |
Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Duodenal Ulcer; Gastritis; Gastroesophag | 1993 |
Treatment of gastroesophageal (acid) reflux with lansoprazole: an overview.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Esophagitis; Gastric Acid; Gastr | 1993 |
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidon | 1996 |
Long-term management of gastroesophageal reflux disease and its complications.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Ulcer Agents; Gastroesophageal Reflux; Hista | 1997 |
[Gastroesophageal reflux disease refractory to medical treatment. Which approach: the pill or the scalpel?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Fundoplication; Gastroesophageal Reflux; Hu | 1997 |
Acid pump inhibitors. The treatment of gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cisapride; Gastroesophag | 1998 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 1999 |
Medical therapy. Management of the refractory patient.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Therapy, Combination; Enzyme Inhibitors; Gastroesophag | 1999 |
[Lansoprazole: an analysis of the clinical trials in the 3 years of 1997-1999].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2000 |
Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Drug Interactions; Duode | 2000 |
Aggressive acid control: minimizing progression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Barrett Esophagus; Enzyme Inhibitors; Gastroesophageal Refl | 2001 |
[H2 receptor antagonists and proton pump inhibitors: principles and rules of use].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Aged; Anti-Ulcer Agents; Benzimidazoles; Child | 2001 |
Shortcomings of the first-generation proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Biological Availability; Cytochrome P-450 E | 2001 |
Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2001 |
Review article: long-term use of proton pump inhibitors in GORD--help or hindrance?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Gastroesophageal Reflux; Humans; Lansopr | 2001 |
[Comparative study of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 2001 |
An overview of the pharmacology, efficacy, safety and cost-effectiveness of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Digestive System Diseases; Duodenal Ulcer; Dyspepsia; Enzym | 2002 |
114 trials available for lansoprazole and Esophageal Reflux
| Article | Year |
|---|---|
Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Topics: Aged; Cough; Dexlansoprazole; Dyslipidemias; Esophagitis; Female; Gastroesophageal Reflux; Globus Se | 2020 |
Use of proton pump inhibitors to treat persistent throat symptoms: multicentre, double blind, randomised, placebo controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophagitis, Peptic; Female; Gastroesophageal R | 2021 |
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Topics: Adult; Aged; Biopsy; Double-Blind Method; Esophagitis, Peptic; Esophagoscopy; Esophagus; Female; Gas | 2018 |
A Clinical Trial of Proton Pump Inhibitors to Treat Children with Chronic Otitis Media with Effusion.
Topics: Acoustic Impedance Tests; Administration, Oral; Audiometry; Audiometry, Pure-Tone; Child; Child, Pre | 2018 |
Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Topics: Adult; Aged; Double-Blind Method; Esophagitis; Female; Gastroesophageal Reflux; Heartburn; Humans; L | 2019 |
Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.
Topics: Adolescent; Asthma; Body Weights and Measures; Child; Cytochrome P-450 CYP2C19; Double-Blind Method; | 2019 |
Is the proton pump inhibitor test helpful in patients with laryngeal symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Drug Administration Sche | 2013 |
Clinical characteristics and effectiveness of lansoprazole in Japanese patients with gastroesophageal reflux disease and dyspepsia.
Topics: Adult; Aged; Dyspepsia; Esophagitis, Peptic; Female; Gastroesophageal Reflux; Heartburn; Humans; Jap | 2014 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole; Dose-Response Relationship, Drug; Doubl | 2013 |
Lansoprazole Is Associated with Worsening Asthma Control in Children with the CYP2C19 Poor Metabolizer Phenotype.
Topics: Adolescent; Asthma; Child; Cytochrome P-450 CYP2C19; Drug Monitoring; Female; Gastroesophageal Reflu | 2015 |
TOPPITS: Trial Of Proton Pump Inhibitors in Throat Symptoms. Study protocol for a randomised controlled trial.
Topics: Clinical Protocols; Feasibility Studies; Gastroesophageal Reflux; Humans; Lansoprazole; Laryngophary | 2016 |
Randomized study of lafutidine vs lansoprazole in patients with mild gastroesophageal reflux disease.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Esophagitis, Peptic; Female; Gastroesophageal Reflux; He | 2016 |
Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Cross-Over Studies; Cytochrome P-450 CYP2C19; Double | 2016 |
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esopha | 2008 |
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esopha | 2008 |
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esopha | 2008 |
Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Esopha | 2008 |
Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Area Under Curve; Aryl Hydr | 2008 |
Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Area Under Curve; Aryl Hydr | 2008 |
Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Area Under Curve; Aryl Hydr | 2008 |
Age-dependent pharmacokinetics of lansoprazole in neonates and infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Area Under Curve; Aryl Hydr | 2008 |
Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Cross-Over Studies | 2009 |
Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Drug-Related Side Effects and Adverse | 2009 |
Comparison of the enteral and intravenous lansoprazole pharmacodynamic responses in critically ill patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Critical Illness; Drug Administration Ro | 2008 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastr | 2009 |
[Evaluation of preferences in patients with gastroesophageal reflux disease and dysphagia concerning treatment with lansoprazole orally disintegrating tablets].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross-Over Studies; Deglutition Disorders; Female; Gastroes | 2009 |
[Lanzoptol efficiency for heartburn alleviation in patients with NERD].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Female; Gastric Acid; Gastric Acid | 2009 |
Omeprazole-Mg 20.6 mg is superior to lansoprazole 15 mg for control of gastric acid: a comparison of over-the-counter doses of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Antacids; Anti-Ulcer Agents; Cross-Over Studies; Dos | 2010 |
Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Chi-Square Distribution; Esophageal pH Monitoring; Esophago | 2010 |
Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Alanine; Anti-Ulcer Agents; Drug Synergism; Drug Ther | 2010 |
Clinical trial: gastric acid suppression in Hispanic adults with symptomatic gastro-oesophageal reflux disease - comparator study of esomeprazole, lansoprazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2010 |
Clinical trial: chest pain caused by presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole vs. placebo.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chest Pa | 2010 |
Dilated intercellular space in chronic laryngitis and gastro-oesophageal reflux disease: at baseline and post-lansoprazole therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Biopsy; Chronic Disease; Dila | 2010 |
Proton pump inhibitor therapy improves symptoms in postnasal drainage.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Chronic Disease; Education, Medical, Continuing; Enz | 2010 |
The effects of three alternative treatment strategies after 8 weeks of proton pump inhibitor therapy for GERD in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Dru | 2011 |
[Lanzoptol efficacy at gastroesophageal reflux disease: results of multicenter study leader].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoscopy, Digestive System; Enzyme Inhibitors; Fema | 2010 |
The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Delayed-Action Preparations; Dexla | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dexlansoprazole; Double-Bli | 2011 |
Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Area Under Curve; Child; Dexlansoprazole; Esoph | 2012 |
Impact of acid inhibition on esophageal mucosal injury induced by low-dose aspirin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aspirin; Cross-Over Studies; Esophagus; Famotidine; Female; | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Dexlansoprazole | 2012 |
Lansoprazole for children with poorly controlled asthma: a randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adolescent; Adrenal Cortex Horm | 2012 |
A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Alanine; Dose-Response Rela | 2012 |
Clinically distinct characteristics in patients younger than 40 years old with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Chest Pain; Chi-Square Distribution; En | 2012 |
Intragastric acidity during the first day following administration of low-dose proton pump inhibitors: a randomized crossover study.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cross-Over Studies; Cytochrome P-450 CYP2C19; Dose-Response Re | 2013 |
On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 2002 |
Effective intra-oesophageal acid suppression in patients with gastro-oesophageal reflux disease: lansoprazole vs. pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationsh | 2003 |
Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Dose-Response Relationship, | 2003 |
Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chest Pain; Female; Gastroe | 2003 |
Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Dose-Response R | 2002 |
Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child; Child, Preschool; Endoscopy, Gast | 2002 |
Lansoprazole in adolescents with gastroesophageal reflux disease: pharmacokinetics, pharmacodynamics, symptom relief efficacy, and tolerability.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Dos | 2002 |
Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Area Under Curve; Body Weight; Child; Ch | 2002 |
The prophylactic use of a proton pump inhibitor before food and alcohol.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Alcohol Drinking; Anti-Ulcer Agents; Double-Blind Me | 2003 |
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cytochrome P-450 Enzyme System; Esophagi | 2003 |
Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Respon | 2003 |
Nutcracker oesophagus: a double-blind, placebo-controlled, cross-over study of the effects of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Ulcer Agents | 2003 |
Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Chi-S | 2003 |
Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30 mg and rabeprazole 20 mg in healthy volunteers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2003 |
Endoscopy-negative reflux disease: what is the value of a proton-pump inhibitor test in everyday clinical practice?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal | 2003 |
Double-blind, randomized controlled study to assess the effects of lansoprazole 30 mg and lansoprazole 15 mg on 24-h oesophageal and intragastric pH in Chinese subjects with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; China; Cross-Over Studies; Double-Blind | 2004 |
The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Chest Pa | 2004 |
Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Benzimidazo | 2004 |
Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
On-demand PPI requirements in patients with endoscopy-negative GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Capsules; Drug Administrati | 2004 |
The effect of Helicobacter pylori eradication on gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Anti-Ulcer Agents; Benz | 2005 |
Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Child; Dose-Response Relatio | 2005 |
Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Comorbidity; Cross-Over Studies; D | 2005 |
A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Circadian Rhyth | 2005 |
Management of symptoms in step-down therapy of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Deglutition Disorders; Endosonography; Enzyme Inhibit | 2005 |
Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Inhalation; Adrenal Cortex Hormones; Adult; | 2005 |
Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Double-Blind Method; Female | 2005 |
Intra-oesophageal acid suppression in complicated gastro-oesophageal reflux disease: esomeprazole versus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Esomeprazole; Esophag | 2006 |
Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Chronic Disease; Cough; Enz | 2006 |
Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2006 |
A proton pump inhibitor, lansoprazole, ameliorates asthma symptoms in asthmatic patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Asthma; Drug Evaluation; | 2006 |
Prospective trial of laparoscopic nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: Seven-year follow-up.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Follow-Up Studies; | 2006 |
Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Alleles; Anti-Ulcer Agents; Ar | 2006 |
Pharmacokinetics and pharmacodynamics of lansoprazole in children 13 to 24 months old with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child, Preschool; Esophagitis; Female; G | 2007 |
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Antacids; Anti-Ulcer Age | 2007 |
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cytochrom | 2007 |
Acid control with esomeprazole and lansoprazole: a comparative dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response | 2007 |
Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms--a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2006 |
Proton pump inhibitors improve acid-related dyspepsia in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Dyspepsia; Female; Gastroesophageal Reflux; Hu | 2007 |
Failures in a proton pump inhibitor therapeutic substitution program: lessons learned.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aluminum Hydroxide; Analysis of Variance; Cross-Over | 2007 |
Increased esophageal mucosal/submucosal blood flow in patients with gastroesophageal reflux disease: normalization by treatment with a proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Endoscopy, Gastrointestinal | 2008 |
Use of acid-suppressing drugs and the risk of bacterial gastroenteritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Bacterial Infections; Enzyme Inhibitors; Femal | 2007 |
Clinical response to 2 dosing regimens of lansoprazole in infants with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 2008 |
Ninety-six-hour wireless oesophageal pH monitoring following proton pump inhibitor administration in NERD patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Esophageal pH Monitoring; Female; | 2008 |
Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 1996 |
Lifetime costs of surgical versus medical treatment of severe gastro-oesophageal reflux disease in Finland.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Distribution; Aged; Chronic Disease; Cost of Ill | 1997 |
Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Double | 1998 |
Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Esophagitis; G | 1997 |
Dose-response relationship of lansoprazole to gastric acid antisecretory effects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Cross-Over | 1998 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition | 1998 |
Speed of onset of oesophageal acid reduction with different proton-pump inhibitors in patients with reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cross-Over Studies; Double-Blind | 1998 |
Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Circadian Rhythm; Female; Gastric Acid; Gastro | 1998 |
Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Cross-Over Studies; Double-Blind Method; Esoph | 1998 |
Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1999 |
Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Cell Count; Double-Blind Method; Female; | 2000 |
Ultrasonographic evaluation of lansoprazole-induced improvement of submucosal injury in patients with gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Double-Blind Method; Endosonograph | 2000 |
Gastric acidity and acid breakthrough with twice-daily omeprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Circadian Rhythm; Cross-Over Stud | 2000 |
Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Aged, 80 and over; Antacids; A | 2000 |
Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy-a prospective, randomized, multi-ce
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Drug Administration Schedul | 2000 |
Lansoprazole in the treatment of gastro-oesophageal reflux disease in childhood.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Child; Child, Preschool; Enzyme Inhibitors; Eso | 2000 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Chronic Disease; Double-Blind Method; Female; Gastroe | 2001 |
Control of intragastric pH with omeprazole 20 mg, omeprazole 40 mg and lansoprazole 30 mg.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Circadian Rhythm; Cross-Over Studies; Dose-Response | 2001 |
Helicobacter pylori and symptomatic relapse of gastro-oesophageal reflux disease: a randomised controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; A | 2001 |
Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind M | 2001 |
High-dose proton-pump inhibitors as a diagnostic test of gastro-oesophageal reflux disease in endoscopic-negative patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cross-Over Studies; Double- | 2001 |
Does short-term treatment with proton pump inhibitors cause rebound aggravation of symptoms?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; | 2001 |
Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Ulcer Agents; Area Under Curve; Child; Chi | 2001 |
Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Drug Administration Schedule; Endoscopy; Enzyme Inhib | 2001 |
Health-Related quality-of-life and quality-days incrementally gained in symptomatic nonerosive GERD patients treated with lansoprazole or ranitidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Double-Blind Method; Drug Adminis | 2001 |
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Cyt | 2001 |
Lansoprazole vs. omeprazole for gastro-oesophageal reflux disease: a pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Anti-Ulcer Agents; Esophagus; | 2002 |
Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Gastro | 2002 |
Helicobacter pylori eradication does not worsen quality of life related to reflux symptoms: a prospective trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2002 |
133 other studies available for lansoprazole and Esophageal Reflux
| Article | Year |
|---|---|
Effects of lansoprazole capsule combined with mosapride citrate tablets on gastric motility, VIP and PG in patients with symptomatic gastroesophageal reflux disease.
Topics: Gastroesophageal Reflux; Humans; Lansoprazole; Morpholines; Tablets | 2022 |
Proton pump inhibitors associated with rapid eye movement sleep behaviour disorder.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Female; Gastroesophageal Reflux; Humans; Lansoprazole | 2021 |
The Role of Endoplasmic Reticulum Stress in Gastroesophageal Reflux Disease Symptoms and Treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Endoplasmic Reticulum Stress; Female; Gastroesophage | 2023 |
Paroxysmal head drops with ataxia-like symptoms presenting as Sandifer syndrome in a 3-year old girl.
Topics: Ataxia; Child, Preschool; Diagnosis, Differential; Dystonia; Female; Gastroesophageal Reflux; Humans | 2020 |
Empirical treatment of outpatients with gastroesophageal reflux disease with proton pump inhibitors: A survey of Chinese patients (the ENLIGHT Study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Asian People; Esomeprazole; Female | 2018 |
Should Proton Pump Inhibitors be Systematically Prescribed in Patients With Esophageal Atresia After Surgical Repair?
Topics: Anastomosis, Surgical; Anastomotic Leak; Child; Child, Preschool; Constriction, Pathologic; Esophage | 2019 |
Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Topics: Adult; Cost-Benefit Analysis; Drug Administration Schedule; Female; Gastroesophageal Reflux; Gastroi | 2019 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Body Mass Index | 2013 |
Signal detection theory approach to gastroesophageal reflux disease: a new method for symptom analysis of impedance-pH data.
Topics: Adult; Electric Impedance; Esophageal pH Monitoring; Esophageal Sphincter, Lower; Female; Gastroesop | 2014 |
Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine.
Topics: Amidohydrolases; Animals; Arginine; Biomarkers; Cardiovascular Diseases; Cells, Cultured; Disease Mo | 2013 |
Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Substitution; Esomeprazole; Gastroesophageal Reflux; H | 2013 |
A high chromogranin A: Is it always a tumor?
Topics: Aged; Chromogranin A; Enterochromaffin-like Cells; Female; Gastroesophageal Reflux; Humans; Lansopra | 2013 |
Fluoroscopic balloon dilatation for caustic esophageal stricture in children: an 8-year experience.
Topics: Adolescent; Anesthesia, General; Anti-Ulcer Agents; Antibiotic Prophylaxis; Burns, Chemical; Caustic | 2013 |
The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders.
Topics: Dyspepsia; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Proton Pump Inhibitors | 2014 |
Reply to the letter by E. Savarino et al. regarding "The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders".
Topics: Dyspepsia; Female; Gastroesophageal Reflux; Humans; Lansoprazole; Male; Proton Pump Inhibitors | 2014 |
High rate of clinical and endoscopic relapse after healing of erosive peptic esophagitis in children and adolescents.
Topics: Adolescent; Anti-Ulcer Agents; Body Mass Index; Child; Child, Preschool; Endoscopy; Esophagitis; Eso | 2014 |
Pharmacogenomic testing: the case for CYP2C19 proton pump inhibitor gene-drug pairs.
Topics: Cytochrome P-450 CYP2C19; Drug Interactions; Gastroesophageal Reflux; Genetic Variation; Humans; Lan | 2014 |
Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia.
Topics: Age Factors; Aged; Body Mass Index; Dyspepsia; Female; Gastroesophageal Reflux; Hernia, Hiatal; Huma | 2015 |
Lifestyle factors and efficacy of lifestyle interventions in gastroesophageal reflux disease patients with functional dyspepsia: primary care perspectives from the LEGEND study.
Topics: Adult; Aged; Causality; Comorbidity; Dyspepsia; Female; Gastroesophageal Reflux; Health Behavior; Hu | 2015 |
Lansoprazole worsens asthma control in poor metabolizers: is nitric oxide involved?
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
Reply: worsening asthma control in children taking lansoprazole: possible mechanisms.
Topics: Asthma; Cytochrome P-450 CYP2C19; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Lansopra | 2015 |
Sticky Palms Following Use of Proton-Pump Inhibitors.
Topics: Administration, Oral; Adult; Drug Eruptions; Esomeprazole; Female; Gastroesophageal Reflux; Hand Der | 2016 |
A 12-month follow-up study on the preventive effect of oral lansoprazole on acute exacerbation of chronic obstructive pulmonary disease.
Topics: Acute Disease; Administration, Oral; Aged; Cytokines; Female; Follow-Up Studies; Forced Expiratory V | 2016 |
Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Case-Control Studies; Colit | 2008 |
Watermelon stomach.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Follow-Up Studies; Gastric Antral Vascular Ectasia; G | 2008 |
Association of laryngopharyngeal manifestations and gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Endoscopy, Digestive System; Esophagitis; Fema | 2009 |
Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Clinical Trials as Topic; Databases, Bibliographic; | 2009 |
[Diagnosis and therapy of gastroesophageal reflux disease with lansoprazole].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 2008 |
[Nocturnal shortness of breath: in asthma look for reflux -- is it worthwhile?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Bronchodilator Agents; Gastroesophageal Reflux; Hum | 2008 |
Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Area Under Curve; Dexlansoprazole; Ga | 2009 |
CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Cli | 2009 |
Dexlansoprazole (Kapidex) for GERD and erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Clinical Trials as Topic; Delayed-Action Preparations; Dexl | 2009 |
Stop the PPI express: they don't keep babies quiet!
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Crying; Gastroesophageal Reflux; Humans; Infant, Newborn; L | 2009 |
Lansoprazole, ranitidine, and metoclopramide: comparison of practice patterns at 4 level III NICUs within one healthcare system.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Monitoring; Gastroesophageal Reflux | 2009 |
Helicobacter pylori-negative gastritis in erosive esophagitis, nonerosive reflux disease or functional dyspepsia patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2010 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clinical | 2009 |
Linear and loglinear structural mean models to evaluate the benefits of an on-demand dosing regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 2009 |
Inappropriate use of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Cross-Sectional Studies; Dyspepsia | 2010 |
Cough syncope induced by gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Bradycardia; Cough; Gastroesophageal Reflux; Humans; Lansop | 2009 |
Linear mucosal defects: a characteristic endoscopic finding of lansoprazole-associated collagenous colitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Colitis, Collagenous; Colonoscopy; | 2010 |
[Clinical analysis of recurrence rate and symptom improvement in gastro-esophageal reflux disease patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Follow-Up Studies; | 2010 |
Dexlansoprazole for the treatment of esophagitis and GERD.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Child; Clinical Trials as Topic; | 2010 |
Novel approaches to inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastric Acid; Gastroesophageal Reflux; H | 2010 |
Safety profile of six months lansoprozole treatment in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Bone Density; Calcium; Child; Child, Preschool; | 2010 |
Do the laryngopharyngeal symptoms and signs ameliorate by empiric treatment in patients with suspected laryngopharyngeal reflux?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Dose-Response Relationship, Drug; Female; Gastroesop | 2011 |
Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Esomeprazole; E | 2011 |
Time to stop blaming gastroesophageal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cough; Diagnosis, Differential; Electric Impedance; Enzyme | 2011 |
Lansoprazole precipitated QT prolongation and torsade de pointes associated with disopyramide.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Arrhythmia Agents; Anti-Ulcer Agents; Disopyrami | 2012 |
Proton pump inhibitors omeprazole, lansoprazole and pantoprazole induce relaxation in the rat lower oesophageal sphincter.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Angiotensins; Animals; Carbachol; Electric Stimulation; Eso | 2011 |
The safety of fetal exposure to proton-pump inhibitors during pregnancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abnormalities, Drug-Induced; Adult; Cohort Studies; Databas | 2012 |
Gastric neuroendocrine carcinoma after long-term use of proton pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Carcinoma, Neuroendocrine; Chromogranin A; Gastrins; Gastro | 2012 |
Acid suppression for reflux disease: "off-the-peg" or a tailored approach?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Gastroesophageal Reflux; Heartburn; Humans; Lansopr | 2012 |
An unexpected cause of infantile failure to thrive.
Topics: Anti-Ulcer Agents; Diagnosis, Differential; Failure to Thrive; Female; Gastroesophageal Reflux; Huma | 2012 |
Trends of outpatient prescription drug utilization in US children, 2002-2010.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Ambulatory Care; Anti-Bacterial Agents; Attenti | 2012 |
[Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Female; Gastroesophageal Reflux; Humans; Lansoprazol | 2012 |
Does oral lansoprazole really reduce gastric acidity in VLBW premature neonates?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Female; Gastric Acid; Gastroesophageal R | 2012 |
A novel once daily microparticulate dosage form comprising lansoprazole to prevent nocturnal acid breakthrough in the case of gastro-esophageal reflux disease: preparation, pharmacokinetic and pharmacodynamic evaluation.
Topics: Acids; Acrylic Resins; Animals; Anti-Ulcer Agents; Delayed-Action Preparations; Gastroesophageal Ref | 2013 |
An evaluation of the clinical implications of acid breakthrough in patients on proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2002 |
Proton pump inhibitors: an update.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Interactions; Esomeprazole; Gastroesop | 2002 |
Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Benzimidazoles; Child; Child, Pres | 2002 |
Functional dyspepsia: bye-bye to PPIs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; China; Dyspepsia; Gastroesophageal R | 2002 |
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aryl Hydrocarbon Hydroxylases; Confidence Intervals; | 2002 |
Chronic cough and gastroesophageal reflux disease: experience with specific therapy for diagnosis and treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Chronic Disease; Cisapride; | 2003 |
Lansoprazole overutilization: methods for step-down therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Drug Costs; Drug Utilization Review; Enz | 2003 |
The comparison of an empiric proton pump inhibitor trial vs 24-hour double-probe Ph monitoring in laryngopharyngeal reflux.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Enzyme Inhibitors; Female; Gastroesophageal Re | 2003 |
Cost-minimization analysis of treatment of gastroesophageal reflux disease. Implications of varying holding time on conclusions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Cost Control; Cost-Benefit Analysis; Databa | 2004 |
Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Child; Cimetidine; Diagnosis, Differential; Enzyme | 2004 |
Persistent acid and bile reflux in asymptomatic patients with Barrett esophagus receiving proton pump inhibitor therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Benzimidazoles; | 2004 |
Pachydermia is not diagnostic of active laryngopharyngeal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2004 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Persistent cough following pulmonary resection: observational and empiric study of possible causes.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Benzamides; Carcinoma, Non-Small-Cell Lung; Chronic D | 2005 |
Rebound acid hypersecretion after long-term inhibition of gastric acid secretion.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Enterochromaffin- | 2005 |
Lack of interaction between atazanavir and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Atazanavir Sulfate; Contraindicat | 2005 |
Rabeprazole controls GERD symptoms in a patient for whom treatment with lansoprazole failed: first report of "cluster GERD.".
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Gastroesophageal Reflux; | 2005 |
Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Drug Admini | 2005 |
Lansoprazole-associated collagenous colitis: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Biopsy; Colitis; Collagen; Colonoscopy; Diagnosis, Differen | 2005 |
[Pharmacogenomical aspects of gastroesophageal reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Benzimida | 2005 |
Frequency of gastroesophageal reflux disease in nonatopic children with asthma-like airway disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Asthmatic Agents; Anti-Ulcer Agents; Asthma; Child; Ch | 2006 |
A decade-long sour-taste sensation successfully treated with a proton-pump inhibitor.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Drug Administration Schedule; Enzyme Inhibitors; Female; Ga | 2005 |
Nasal pain disrupting sleep as a presenting symptom of extraesophageal acid reflux in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Child, Preschool; Diet; Gastroesophageal | 2005 |
Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esomeprazole; Gastroesop | 2005 |
Factors influencing the shift of patients from one proton pump inhibitor to another: the effect of direct-to-consumer advertising.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Advertising; Cohort Studies; Cost Sharing; Drug Utilization | 2005 |
Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastric Acidity Determination; Ga | 2005 |
Gastro-oesophageal reflux disease in 'difficult-to-control' asthma: prevalence and response to treatment with acid suppressive therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Asthma; Cohort Studies; Female; Forced Expiratory | 2006 |
Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Drug Administration Schedule; Enzyme Inhibi | 2006 |
Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adolescent; Anorexia; Anti-Ulcer Agents; Ch | 2006 |
Efficacy of low-dose lansoprazole in the treatment of non-erosive gastrooesophageal reflux disease. Influence of infection by Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Female; Gastroesophageal Reflux; Helic | 2006 |
[Effects of proton pump inhibitor on airway hyperresponsiveness in asthmatics with gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Female; Gastroesophageal Reflux; | 2006 |
The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Gastroesophageal Reflux; Humans; | 2006 |
Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Cohort Studies; Female; Gastroeso | 2007 |
Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Distribution; Child; Child, Preschool; Cohort Studies; | 2007 |
Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Cost Sav | 2007 |
Key points in the management of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Endoscopy, Gastrointestinal; Enzyme Inhibitors; Esophageal | 2007 |
Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Asthma; Biomarkers; Breath Tests; Comorbidity; Dinoprost; F | 2007 |
[Otorhinolaringologyc approach of the chronic cough. Clinical case].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Antitussive Agents; Chronic Disease; Cou | 2007 |
[A case of gastroesophageal reflux disease with marked eosinophilia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Eosinophilia; Esophagitis, Peptic; Female; Gastroesop | 2007 |
[Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Cost-Benefit Analysis; Decision Support Techniques; Drug Co | 2007 |
Healing of severe reflux esophagitis with PPI does not improve esophageal dysmotility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Esophageal Motility Disorders; Eso | 2007 |
Acceptability of lansoprazole orally disintegrating tablets in patients with gastro-oesophageal reflux disease : ACEPTO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and | 2007 |
Proton pump inhibitor utilization patterns in infants.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Age Factors; Anti-Ulcer Agents; Drug Administration Schedul | 2007 |
Superior mesenteric artery syndrome: an uncommon cause of feeding intolerance in infancy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dexamethasone; Enteral Nutrition; Gastroesophageal Reflux; | 2008 |
Pharmacological compliance and acceptability of lansoprazole orally disintegrating tablets in primary care.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, N | 2008 |
[Drug treatment and surgical indications in gastroesophageal reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Fundoplication | 2007 |
Evidence for the ''paradox'' association between hypertensive lower esophageal sphincter and gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Angina Pectoris; Deglutition Disorders; Esophageal S | 2008 |
Persistent atrial fibrillation associated with gastroesophageal reflux accompanied by hiatal hernia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Aged; Anti-Ulcer Agents; Atrial Fibri | 2008 |
[General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Costs and Cost Analysis; Esomepra | 2008 |
[Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Duodenal Ulcer; Enzyme Inhi | 1995 |
Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Anti-Ulcer Agents; Barrett Esophag | 1997 |
A prospective follow-up study of 5669 users of lansoprazole in daily practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 1997 |
Acid control and regression of Barrett's esophagus: is the glass half full or half empty?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Circadian Rhythm; Dru | 1997 |
Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Barrett Esophagus; Esophagus; Fema | 1998 |
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Circadian Rhythm; Female; G | 1998 |
Development of a health-related quality-of-life questionnaire for individuals with gastroesophageal reflux disease: a validation study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Re | 1999 |
Assessment of patient satisfaction with a formulary switch from omeprazole to lansoprazole in gastroesophageal reflux disease maintenance therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; California; Cost Savings; C | 1999 |
The acid test for formulary policy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Costs and Cost Analysis; Formularies as | 1999 |
Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Costs and Cost Analysis; Enzyme Inhibitors; Female; G | 2000 |
How do we offer clinical relief to patients with gastro-oesophageal reflux disease?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; | 2000 |
Controlling acid reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Gastroesophageal Reflux; Humans; Hydrogen-Ion Concentration | 1999 |
Clinical and humanistic outcomes in patients with gastroesophageal reflux disease converted from omeprazole to lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Female; Gastroesophageal Re | 2000 |
Laryngopharyngeal sensory deficits in patients with laryngopharyngeal reflux and dysphagia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Deglutition Disorders; Fema | 2000 |
Asymptomatic giardiasis--an association with proton pump inhibitors?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Gastroesophageal Reflux; Giardias | 2000 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Laryngopharyngeal reflux symptoms improve before changes in physical findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Female; Follow-Up Studie | 2001 |
Treatment of gastroesophageal reflux disease: to step or not to step.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Enzyme Inhibitors; Gastroesophageal Reflux; Heartburn; Hist | 2001 |
Impact of a formulary change in proton pump inhibitors on health care costs and patients' symptoms.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Female; Formularies as Topic; Gastroesophageal Reflux; Heal | 2001 |
The treatment of gastroesophageal reflux disease with proton-pump inhibitors and its implications on managed care--pharmacoeconomics and its application to antisecretory drugs: a case study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; California; Clinical Trials as Topic; En | 2001 |
[Laryngeal manifestations of gastroesophageal reflux disease (GERD) in pediatric patients: the usefulness of therapeutic (proton pump inhibitor (PPI)) trials].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Child; Child, Preschool; Gastroesophageal Reflux; Humans; I | 2001 |
Laryngospasm: an atypical manifestation of severe gastroesophageal reflux disease (GERD).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Enzyme Inhibito | 2001 |
[Lansoprazole-associated collagenous colitis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Colitis; Collagen; Female; Gastroesophageal Reflux; | 2001 |
In support of "step-up therapy" for gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Dose-Response Relationship, Drug; Drug Administration Sched | 2002 |
Spontaneous resolution of multiple fundic gland polyps after cessation of treatment with lansoprazole and Nissen fundoplication: a case report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Enzyme Inhibitors; Female; Fundoplication; Gastric Fu | 2002 |
Proton pump inhibitors or surgery for gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clinical Trials as Topic; Enzyme Inhibit | 2002 |
Laparoscopic fundoplication versus lansoprazole for gastro-oesophageal reflux disease. A pH-metric comparison.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Enzyme Inhibitors; Female; Fundop | 2002 |
Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Evidence-Based Medicine; Gastroes | 2002 |
Protection against aspiration with the Proseal laryngeal mask airway.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anesthesia, General; Female; Follow-Up Studies; Gastr | 2002 |